Contents

	P
CO PO A E INFO MA ION	2
FINANCIAL HIGHLIGH	4
MANAGEMEN DI C ION AND ANAL I	5
CO PO A E GO E NANCE AND O HE INFO MA ION	34
CON OLIDA ED BALANCE HEE	47
PA EN COMPAN ' BALANCE HEE	52
CON OLIDA ED INCOME A EMEN	56
PA EN COMPAN ' INCOME A EMEN	59
CON OLIDA ED A EMEN OF CA H FLO	61
PA EN COMPAN ' A EMEN OF CA H FLO	64
CON OLIDA ED A EMEN OF CHANGE IN HA EHOLDE 'EQ I	66
PA EN COMPAN ' A EMEN OF CHANGE IN HA EHOLDE 'EQ I	68
NO E O HE FINANCIAL A EMEN	70
DEFINI ION	173

Corporate Information

B D

Executive Directors

M. G AN *(C)*
M . ANG L
M. ANG J

Non-executive Directors

M. QIN H
M. LI C
M. *(A 4, 2026)*

Independent Non-executive Directors

M . HONG
M . JIN L
M. E O *(A 30, 2026)*

At C

M . HONG *(C)*
M. LI C
M . JIN L

N C

M. E O *(C)*
M. G AN
M . JIN L

C

M . JIN L *(C)*
M . HONG
M. E O

M C

M. G AN *(C)*
M . HONG
M. QIN H

C

M. N *(C)*
M . AN *(A 30, 2026)*
M. IE
M. QIAN C
M. *(14, 2026)*

C

M. ANG J
M. ONG C *(10, 2026)*

At

M. G AN
M. ANG J *(A 10, 2026)*
M. ONG C *(10, 2026)*

At

BDO C LLP

L A H K L

C C

H O O P C

D
P C

Corporate Information

P P B
H K

40/F, D F C
248 Q ' E

H K

H H

C H K I L
1712-1716, 17 F
H C
183 Q ' E

H K

C

2120

C '

. .

I

: (86) 577 8877 1689
F : (86) 577 8878 9117
E : @ .

Financial Highlights

P F D I

	For the six months ended June 30,	
	2026	2025
	(RMB'000)	(MB'000)
	(Unaudited)	(t.)
t	829,481	738,562
P	23,715	41,980
I	1,528	15,210
N	22,187	26,769
N t C	33,773	36,530
P t -	-11,586	-9,761

	As at		A
	June 30, 2026	D	31, 2025
	(RMB'000)		(MB'000)
	(Unaudited)		(At.)
	2,924,927		3,025,567
	1,604,226		1,713,937
t	1,320,701		1,311,630
E t t C	1,206,196		1,187,819
N -	114,505		123,811

	For the six months ended June 30,	
	2026	2025
	(RMB'000)	(MB'000)
	(Unaudited)	(t.)
N	111,549	198,522
N t	-52,515	-126,962
N	-35,720	6,317
N t	23,240	77,874

Management Discussion and Analysis

B O

I 2026, . M , . N - . D P , G - . I , , .

I 2026, G MB829.5 , 12.3% . A , MB709.7 , 2.7% . D P , G C MB33.8 , 7.5% . A J 30, 2026, G ' 35 (D 31, 2025: 34), (P I H), 11,308 (D 31, 2025: 11,508).

Management Discussion and Analysis

Psychiatric Healthcare Business

I 2026, A M H [illegible] F [illegible] G [illegible] D [illegible] P [illegible] G [illegible] L [illegible]

A J 30, 2026, G [illegible] 26 [illegible] G [illegible] J 30, 2026:

	As at June 30, 2026		A D 31, 2025	
	Number of institutions	Number of operating beds	N [illegible]	N [illegible]
[illegible] P	16	6,580	16	6,580
[illegible] P	10	1,948	10	2,128
	26	8,528	26	8,708

Management Discussion and Analysis

Elderly Healthcare Business

[illegible]

A [illegible] 30, 2026, [illegible] 8 [illegible] 1 [illegible] 30, 2026:

	As at June 30, 2026		A D [illegible] 31, 2025	
	Number of institutions	Number of operating beds	[illegible]	[illegible]
[illegible]	7	2,610	6	2,630
H [illegible]	1	170	1	170
	8	2,780	7	2,800

L [illegible] C [illegible]

Management Discussion and Analysis

F

G t- 1 1、 1 t- 1 1 MB829.5 、t-1 1 P 1 、(1 、 、 Jt- 30, 2025: MB738.6), 1 1 1 12.3% 1 、 1 、 2025. A , 1 t- 1 1 、 t- 、 MB709.7 (1 、 、 Jt- 30, 2025: MB690.9), 1 1 1 2.7% 1 、 1 、 2025. Dt-1 1 P 1 、, 1 1 1 G t- ' 、 25.0% (1 、 、 Jt- 30, 2025: 24.2%). 1 1 1 G t- 1 、 MB204.4 , 1 1 1 8.0% 1 、 1 、 2025. Dt-1 1 P 1 、, 1 1 t- 1 、 1 C t- 、 MB33.8 , 1 1 、 1 7.5% 1 、 1 、 2025. Dt-1 1 P 1 、, 1 、 1 1 G t- t- 、 MB111.5 (1 、 、 Jt- 30, 2025: MB198.5), 1 1 、 1 43.8% 1 、 1 、 2025.

Revenue and Cost of Revenue

G t- 1 1 t- 1 t- 1 : ( ) 1 t- 1 1 、 ; ( ) 1 t- 1 1 1 -1 、 t- ; 、( ) 1 1 t- 1 、 1 t- .

1 1 、 1 t- 1 1 、 、 、:

	For the six months ended June 30,	
	2026	2025
	(RMB'000)	(MB'000)
	(Unaudited)	(t-、 、)
Revenue from operating owned hospitals	709,707	690,903
I t-、 : t- 1 1 1		
t-	494,396	489,760
t- 1 、 1 1 t-	215,311	201,143
Revenue from other healthcare related business	119,410	46,753
Other revenue not related to healthcare business	364	906
Total revenue	829,481	738,562

Management Discussion and Analysis

[illegible]

[illegible]

[illegible]

	For the six months ended June 30,	
	2026	2025
	(RMB'000)	(MB'000)
	(Unaudited)	([illegible])
Billing Revenue from owned hospitals	695,921	722,440
I [illegible]: [illegible]		
[illegible]	488,038	515,802
[illegible]	207,883	206,638
Less: Variable considerations	-13,786	31,537
Revenue from operating owned hospitals – net	709,707	690,903

[illegible] MB695.9 [illegible] 3.7% [illegible] 2025, [illegible] MB-13.8 [illegible] MB45.3 [illegible] 2025. [illegible] -2.0% ([illegible] 30, 2025: 4.4%).

Management Discussion and Analysis

[illegible] B [illegible] G [illegible] :

	For the six months ended June 30,	
	2026	2025
	(RMB'000)	(MB'000)
	(Unaudited)	([illegible])
Billing Revenue from psychiatric healthcare business	488,038	515,802
C [illegible]	352,818	351,923
G [illegible]	135,220	163,879
Billing Revenue from elderly healthcare business	207,883	206,638
C [illegible]	179,396	171,970
G [illegible]	28,487	34,668

D [illegible] P [illegible] G [illegible] B [illegible] MB695.9 [illegible] MB26.5 [illegible] 2025, [illegible] B [illegible] G [illegible] H [illegible] K H [illegible] K H [illegible] P C H [illegible] B H [illegible] D [illegible] P [illegible] G [illegible] B [illegible] 17.5% [illegible] 2025, [illegible]

Management Discussion and Analysis

[illegible]

Psychiatric healthcare business

	For the six months ended June 30, 2026 (Unaudited)	2025 ([illegible])
Inpatients		
I[illegible]	8,528	8,918
E[illegible]	1,543,568	1,614,158
[illegible] *(%)*	90.3	88.1
N[illegible]	1,394,373	1,422,112
[illegible] *(RMB'000)*	368,484	387,395
A[illegible] *(RMB)*	264	272
P[illegible] *(RMB'000)*	39,945	44,393
A[illegible] *(RMB)*	29	31
Total inpatient revenue *(RMB'000)*	408,429	431,788
Total average inpatient spending per bed-day *(RMB)*	293	304
Outpatients		
N[illegible]	208,483	308,444
[illegible] *(RMB'000)*	20,153	21,140
A[illegible] *(RMB)*	97	69
P[illegible] *(RMB'000)*	59,456	62,873
A[illegible] *(RMB)*	285	204
Total outpatient revenue *(RMB'000)*	79,609	84,013
Total average outpatient spending per visit *(RMB)*	382	272
Total treatment and general healthcare services revenue *(RMB'000)*	388,637	408,535
Total pharmaceutical sales revenue *(RMB'000)*	99,401	107,266

Management Discussion and Analysis

D P , B MB408.4 , 5.4% 2025, K H , K H , K H , N H H K H . B B 83.7% (30, 2025: 83.7%).

D P , B MB79.6 , 5.2% 2025, 32.4% 40.4%. B B 16.3% (30, 2025: 16.3%).

D P , , B 4.9% 2025, 79.6% B (30, 2025: 79.2%); B 7.3% 2025, 20.4% B (30, 2025: 20.8%). A , B B 9.8% (30, 2025: 10.3%), B 74.7% (30, 2025: 74.8%).

Management Discussion and Analysis

Elderly healthcare business

	For the six months ended June 30,	
	2026	2025
	(Unaudited)	([illegible])
Inpatients		
I [illegible]	2,780	2,900
E [illegible]	499,580	499,230
[illegible] *(%)*	93.8	85.3
N [illegible]	468,799	425,751
[illegible] *(MB'000)*	154,590	151,629
A [illegible] *(MB)*	330	356
P [illegible] *(MB'000)*	45,691	44,099
A [illegible] *(MB)*	97	104
Total inpatient revenue *(RMB'000)*	200,281	195,728
Total average inpatient spending per bed-day *(RMB)*	427	460
Outpatients		
N [illegible]	24,505	33,327
[illegible] *(MB'000)*	2,956	4,960
A [illegible] *(MB)*	121	149
P [illegible] *(MB'000)*	4,646	5,950
A [illegible] *(MB)*	190	179
Total outpatient revenue *(RMB'000)*	7,602	10,910
Total average outpatient spending per visit *(RMB)*	311	327
Total treatment and general healthcare services revenue *(RMB'000)*	157,546	156,589
Total pharmaceutical sales revenue *(RMB'000)*	50,337	50,049

Management Discussion and Analysis

Dt P , B t t MB200.3 , 2.3% 2025, t 10.1% t - 2025, t H t H . B t B t 96.3% (30, 2025: 94.7%).

Dt P , t B t MB7.6 , 30.3% 2025, t 26.5% t P C H 4.9% t . B t B t 3.7% (30, 2025: 5.3%).

Dt P , t , B t 0.6% 2025, t 75.8% B t (30, 2025: 75.8%); B t 0.6% 2025, t 24.2% B t (30, 2025: 24.2%). A , B t B t 22.8% (30, 2025: 22.5%), t B t 61.1% (30, 2025: 54.5%).

Management Discussion and Analysis

[illegible]

	For the six months ended June 30,	
	2026	2025
	(RMB'000)	(MB'000)
	(Unaudited)	([illegible])
P [illegible]	145,891	149,554
E [illegible]	234,229	233,447
D [illegible]	68,127	57,175
C [illegible]	34,739	33,470
[illegible]	6,181	5,413
O [illegible]	43,047	44,834
Cost of revenue of owned hospitals	532,214	523,893

Dt [illegible] P [illegible], [illegible] Gt [illegible] MB532.2 [illegible] 1.6% [illegible] 2025. [illegible] : ( ) 2.4% [illegible] 2025; ( ) 0.3% [illegible] 2025; ( ) 19.2% [illegible] 2025.

I [illegible] 27.4% ([illegible] Jt 30, 2025: 28.6%), [illegible] 44.0% ([illegible] Jt 30, 2025: 44.6%), [illegible] 12.8% ([illegible] Jt 30, 2025: 10.9%).

Management Discussion and Analysis

[illegible]

[illegible] G[illegible] MB119.4 [illegible] MB72.5 ([illegible] 30, 2025: MB28.3); [illegible] 646.2% [illegible] 2025, [illegible] G[illegible] 2025. [illegible] G[illegible]:

I	For the six months ended June 30, 2026 (RMB'000)	2025 (MB'000)
[illegible]		
[illegible]	72,543	28,288
[illegible]	41,972	5,625
O[illegible]	4,895	12,840
Revenue from the other healthcare related business	119,410	46,753

Management Discussion and Analysis

Gross Profit and Gross Profit Margin

D[illegible] P[illegible], [illegible] G[illegible] [illegible] MB204.4 [illegible] 8.0% [illegible] 2025; [illegible] MB177.5 [illegible] 6.3% [illegible] 2025. [illegible]:

	For the six months ended June 30,	
	2026	2025
	(Unaudited)	([illegible])
O[illegible]	25.0%	24.2%
P[illegible]	28.6%	28.4%
E[illegible]	16.7%	16.4%
O[illegible]	22.5%	46.6%
Consolidated gross profit margin	24.6%	25.6%

D[illegible] P[illegible], [illegible] G[illegible] 24.6% ([illegible] 30, 2025: 25.6%).

Management Discussion and Analysis

Tax and Surcharge

D[illegible] P[illegible], [illegible] G[illegible] [illegible] MB6.2 ([illegible] J[illegible] 30, 2025: MB5.1).

Selling Expenses

D[illegible] P[illegible], G[illegible] [illegible] MB3.7 ([illegible] J[illegible] 30, 2025: MB3.7), [illegible] I[illegible] [illegible] 0.5% G[illegible] [illegible] ([illegible] J[illegible] 30, 2025: 0.5%).

Administrative Expenses

D[illegible] P[illegible], [illegible] G[illegible] [illegible] [illegible] G[illegible] [illegible]:

	For the six months ended June 30,	
	2026	2025
	(RMB'000)	(MB'000)
	(Unaudited)	([illegible])
E [illegible]	69,009	71,695
D [illegible]	16,490	15,388
P[illegible]	5,739	4,666
[illegible]	1,719	2,039
O [illegible]	24,452	28,032
Total administrative expenses	117,409	121,820

D[illegible] P[illegible], [illegible] G[illegible] [illegible] MB117.4 [illegible] 3.6% [illegible] 2025, [illegible] 3.7% [illegible] 2025. D[illegible] P[illegible], [illegible] 16.5% G[illegible] [illegible] ([illegible] J[illegible] 30, 2025: 17.6%).

Management Discussion and Analysis

Research and Development Expenses

D P G t t G t :

	For the six months ended June 30,	
	2026	2025
	(RMB'000)	(MB'000)
	(Unaudited)	(t)
C	11,909	11,923
D	2,993	2,933
C t I	709	807
Total	15,611	15,663

D P G t ' t MB15.6 (J 30, 2025: MB15.7), 0.3% 2025. t 2.2% G t ' t (J 30, 2025: 2.3%).

Management Discussion and Analysis

Finance Expenses – Net

Ot [illegible] t [illegible] , [illegible] t [illegible] , [illegible] . [illegible] t [illegible] :

	For the six months ended June 30,	
	2026	2025
	(RMB'000)	(MB'000)
	(Unaudited)	(t [illegible])
I [illegible]	-1,877	-587
F [illegible]	73	2
B [illegible]	12,550	13,723
I [illegible]	4,258	4,654
I [illegible]	1,927	3,682
O [illegible]	1,199	533
Finance expenses – net	18,130	22,007

Dt [illegible] P [illegible] , [illegible] G [illegible] t [illegible] MB18.1 , [illegible] MB3.9 [illegible] 2025, [illegible] MB1.2 [illegible] 2025, [illegible] t [illegible] G [illegible] t [illegible] ; [illegible] MB1.8 [illegible] 2025, [illegible] t [illegible] .

Management Discussion and Analysis

Investment Income

Ot-ɹ t-、 ɹ / t- 、 ɹ t- t- 、,
ɹ ɹ 、 - ɹ t- , ɹ 、 、 ɹ ɹ 、 、
ɹ ɹ 、t- . ɹ ɹ 、 t-ɹ
ɹ ɹ 、 、 、:

	For the six months ended June 30,	
	2026	2025
	(RMB'000)	(MB'000)
	(Unaudited)	(t-、 、)
ɹ / t- 、 ɹ t- 、 ɹ t- 、	3,177	-1,206
G 、 - ɹ t-	5,864	5,033
G ɹ 、 、 ɹ ɹ 、	-1,994	–
G ɹ ɹ 、t-	–	5
	7,047	3,832

Dt-ɹ ɹ P ɹ 、, t-ɹ t- 、 MB7.0 .

Credit Impairment Losses

Dt-ɹ ɹ P ɹ 、, ɹ 、 ɹ t- 、 MB17.9 (ɹ 、 、 Jt- 30, 2025: MB-7.6).

Losses/gains from Disposal of Assets

Dt-ɹ ɹ P ɹ 、, ɹ 、 t- 、 MB0.05 (ɹ 、
ɹ 、 、 Jt- 30, 2025: MB1.3).

Management Discussion and Analysis

Non-Operating Income and Non-Operating Expenses

O - t t - t t - t :

	For the six months ended June 30,	
	2026	2025
	(RMB'000)	(MB'000)
	(Unaudited)	(t)
G	–	4
D	–	6
P	1,091	
O -	699	56
Non-operating income	1,790	66
L - t	264	794
D	49	734
E t	1,128	549
O -	16,533	1,722
Non-operating expenses	17,974	3,799

D P - G t t MB1.8 MB1.7 D P - G t MB18.0 t MB14.8 - 2025.

Income Tax Expense

D P MB1.5 (J 30, 2025: MB15.2), 90.0% 2025. D P J 30, 2025, t 6.4% 36.2% .

Management Discussion and Analysis

F P

Inventory

A J 30, 2026, MB43.8 (D 31, 2025: MB46.0), .

Accounts Receivable

A J 30, 2026, MB400.9 (D 31, 2025: MB462.9), 13.4% D 31, 2025, - - .

D P , , G 94 (30, 2025: 122).

Other Receivables and Prepayments

A J 30, 2026, MB90.7 (D 31, 2025: MB93.6).

Long-term Equity Investments

A J 30, 2026, - MB95.9 (D 31, 2025: MB95.9).

Other Non-current Financial Assets

A J 30, 2026, - MB23.9 (D 31, 2025: MB28.1), G ' C J M H I E I F P (L P) (重慶金浦醫療健康服務產業股權投資基金合夥企業(有限合夥)).

Fixed Assets

A J 30, 2026, MB1,175.0 (D 31, 2025: MB1,159.4).

Construction in Progress

A J 30, 2026, MB18.0 (D 31, 2025: MB13.1).

Management Discussion and Analysis

Right-of-use Assets

A Jt 30, 2026, - t MB176.8 (D 31, 2025: MB192.4).

Intangible Assets

A Jt 30, 2026, MB256.8 (D 31, 2025: MB285.8).

Goodwill

A Jt 30, 2026, MB126.5 (D 31, 2025: MB126.5).

Long-term Prepaid Expenses

A Jt 30, 2026, - MB99.5 (D 31, 2025: MB121.6), t MB2.7 t P MB24.7 .

Deferred Tax Assets

A Jt 30, 2026, MB52.6 (D 31, 2025: MB55.3).

Accounts Payable

A Jt 30, 2026, t MB124.0 (D 31, 2025: MB160.8).

Receipts in Advance

A Jt 30, 2026, MB38.3 (D 31, 2025: MB23.3).

Other Payables

A Jt 30, 2026, MB83.6 (D 31, 2025: MB91.9).

Management Discussion and Analysis

L t, C t

G t :

	For the six months ended June 30,	
	2026	2025
	(RMB'000)	(MB'000)
	(Unaudited)	(t,)
N	111,549	198,522
N t,	-52,515	-126,962
N t,	-35,720	6,317
N t	23,240	77,874

Net Cash Generated from Operating Activities

D P , t MB111.5 , t MB33.8 , t MB17.9 MB83.8 . C t MB-16.0 .

Net Cash Used in Investing Activities

D P , t t MB52.5 , t t MB62.3 , t L t K H , L H L C H .

Net Cash Used in Financing Activities

D P , t t MB35.7 .

Significant Investment, Acquisition and Disposal

G t , t , t J 30, 2026.

A , G t , t B , t .

Management Discussion and Analysis

I 、 、 、

Bank Borrowings

A Jt 30, 2026, 11 G t t 、 MB940.7 (D 31, 2025: MB989.2), 、t 11 MB268.0 、 11 MB219.5 、t 1 P 1 、.

Contingent Liabilities

A Jt 30, 2026, G t 、 1 t 1 t 、 1 G t ' 1 1 .

Asset Pledge

G t ' t K H 、 、 1 1 1 1 1 t 1 、 t Lt D 1 N .826751, t Lt D 1 N .826750, (2016) t E N .0010144, (2016) t E N .0010142, (2021) t E N .0081628, t (2015) N .1-11836 、 t (2015) N .1-11833 C M B t L t - 1 , 、 (2017) C C t E N .0018361 I 、t 1 、 C 1 B C Ot t - 1 . A Jt 30, 2026, t 、 、 MB382.6 ; Lt H 、 、 1 1 1 1 1 t 1 、 (2020) t E N .0068897 B C t t C 1 C t - 1 . A Jt 30, 2026, t 、 、 MB108.1 ; J t t H 、 、 1 1 1 1 1 t 1 、 (2022) J t E C 1 N .0002503, 、 t 、 、 1 t 1 1t 1 N .331122202000043 J t t 1 C 1 B t t t - 1 . A Jt 30, 2026, t 、 、 MB35.0 ; Qt t H 、 、 1 1 1 1 1 t 1 、 (2022) Qt t E N .0045588 C CI IC B t B . A Jt 30, 2026, t 、 、 MB55.7 、 L t K H 、 、 1 1 1 1 1 t 1 、 (2023) L t E N . 0004112 C CI IC B t B . A Jt 30, 2026, t 、 、 MB71.3 .

Management Discussion and Analysis

Lease Liabilities

G[illegible] A[illegible] 30, 2026, [illegible] MB40.5 [illegible] MB134.6 [illegible]

Financial Instruments

G[illegible] C[illegible]

Exposure to Fluctuation in Exchange Rates

Management Discussion and Analysis

E t I

I G , C E I 2018 K H C ., L . (E I), C 2017 13, 2018. I C , A , B C , , E I C , E I , B 24, 2021. , C M 29, 2018, M 30, 2018, M 14, 2021, 18, 2021 25, 2021.

E I , 165 , 1,818,529 . P 23 , 180,516 . P ( ) 13 , 540,229 . A , 8 , 79,274 . A , E I 193 , 2,460,000 . 3.49% C 48 MB10.47 .

A 2,460,000 E I 18, 2021, P E I . , E I 30, 2026.

Management Discussion and Analysis

D[illegible] 30, 2026, [illegible] E[illegible]

Name/Category of Grantee	Date of Grant	Vesting Date (Unlocking Date)	Grant Price (RMB/ Share)	Balance of Incentive Shares Granted but not Vested as at January 1, 2026	Balance of Incentive Shares Granted and Vested as at January 1, 2026	Granted during the Reporting Period	Vested (Unlocked) during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Balance of Incentive Shares Granted but not Vested as at June 30, 2026
D[illegible]										
M[illegible]ANG L[illegible]	[illegible] 18, 2021	[illegible] 28, 2022	10.47		248,328					
[illegible]										
M[illegible]IE	[illegible] 18, 2021	[illegible] 28, 2022	10.47		4,776					
O[illegible]										
M[illegible] ([illegible] M[illegible]ANG H[illegible])	[illegible] 18, 2021	[illegible] 28, 2022	10.47		28,653					
M[illegible]ANG H[illegible] ([illegible] M[illegible]ANG L[illegible])	[illegible] 18, 2021	[illegible] 28, 2022	10.47		95,511					
M[illegible]ANG B[illegible] ([illegible]) (N[illegible] M[illegible]ANG L[illegible] M[illegible]ANG H[illegible])	[illegible] 18, 2021	[illegible] 28, 2022	10.47		4,776					
M[illegible] Q[illegible] ([illegible]) ([illegible] M[illegible])	[illegible] 18, 2021	[illegible] 28, 2022	10.47		4,776					
M[illegible]G AN[illegible] ([illegible] M[illegible]G AN[illegible])	[illegible] 18, 2021	[illegible] 28, 2022	10.47		19,102					
M[illegible]N F[illegible] ([illegible])	[illegible] 18, 2021	[illegible] 28, 2022	10.47		14,327					
M[illegible]N H (N[illegible] M[illegible]ANG L[illegible] M[illegible]ANG H[illegible])	[illegible] 18, 2021	[illegible] 28, 2022	10.47		30,563					

Management Discussion and Analysis

Name/Category of Grantee	Date of Grant	Vesting Date (Unlocking Date)	Grant Price (RMB/Share)	Balance of Incentive Shares Granted but not Vested as at January 1, 2026	Balance of Incentive Shares Granted and Vested as at January 1, 2026	Granted during the Reporting Period	Vested (Unlocked) during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Balance of Incentive Shares Granted but not Vested as at June 30, 2026
M . HANG L t. ( )	J. 18, 2021	J. 28, 2022	10.47		4,776					
(- M. G AN)										
M ( )	A. t. 20, 2018	J. 28, 2022	10.47		133,715					
	A 16, 2021	J. 28, 2022	10.47		47,755					
C P O E	A. t. 20, 2018	J. 28, 2022	10.47		1,605,540					
	A. t. 26, 2019	J. 28, 2022	10.47		180,516					
	A 16, 2021	J. 28, 2022	10.47		36,886					
					2,460,000					

A E t. I D C

Management Discussion and Analysis

H A

C L P C A A C H A 2023 C 27, 2023. C 8, 2023 C 27, 2023, A 12, 2024, A 23, 2024 J 18, 2024.

P H A C H A H A C H - C C H H A 5% (3,730,015) C

Management Discussion and Analysis

D[illegible] Ju[illegible] 30, 2026, [illegible] H [illegible] A [illegible]
[illegible] :

Name/Category of Grantee	Date of Grant	Grant Price (RMB/Share)	Number of Shares Granted but not Vested as at January 1, 2026	Number of Shares Granted during the Reporting Period	Closing Price of Relevant Shares Immediately before the Date of Grant of Awards during the Reporting Period (HK$/Share)	Fair Value of Relevant Shares on the Date of Grant during the Reporting Period (HK$/Share)	Number of Shares Vested during the Reporting Period	Weighted Average Closing Price of Relevant Shares Immediately before the Date of Vesting of Awards during the Reporting Period (HK$/Share)	Number of Shares Lapsed during the Reporting Period	Number of Shares Cancelled during the Reporting Period	Number of Shares Granted but not Vested as at June 30, 2026
Directors											
ANG L [illegible]	A [illegible] 23, 2024	0	74,475				24,825	9.30			49,650
	A [illegible] 23, 2024	7	37,500				12,500	9.30			25,000
ANG J	A [illegible] 23, 2024	0	44,325				14,775	9.30			29,550
	A [illegible] 23, 2024	7	37,500				12,500	9.30			25,000
Five Individuals with Highest Emoluments (Excluding Directors)											
[illegible]	A [illegible] 23, 2024	7	22,500				7,500	9.30			15,000
[illegible]	A [illegible] 12, 2024	0	43,125				14,375	9.00			28,750
	A [illegible] 23, 2024	7	22,500				7,500	9.30			15,000
E M [illegible]	A [illegible] 12, 2024	0	15,750				5,250	9.00			10,500
Other Employees (Excluding Directors and Five Individuals with Highest Emoluments)											
E	A [illegible] 12, 2024	0	94,650				31,300	9.00			62,600
	A [illegible] 23, 2024	7	296,250				98,750	9.30			197,500
	Ju[illegible] 18, 2024	7	241,500				79,500	8.20	12,750		146,250
			930,075				308,775		12,750		604,800

Management Discussion and Analysis

N 1: H A :

Vesting Period	Vesting Time	Vesting Percentage
F	F 12	25%
	F 12 24	25%
	F 24 36	25%
F	F 36 48	25%

Corporate Governance and Other Information

A C I I

C A C 3.21 3.22 H K L CG C A C B . A 30, 2026, A C - D , M . HONG (A C) M . JIN L , - D , M . LI C . A C G ' 30, 2026 , , .

I D

B P I D . . B 2026 MB1.80 ( ) 10 C . A IN E IM E L ANNO NCEMEN FO HE I MON H ENDED J NE 30, 2026 C , C 70,399,100 . A C MB12,671,838 ( ), 37.5% P . P I D MB. D MB H H K . P I D H K H K MB P ' B C P I D (. . EGM C). 2026 EGM C .

A 2026 4, 2026, . F P I D , H 10, 2026 15, 2026 ( ). P I D O 5, 2026 D (15, 2026). I P I D , H C H K I L 1712-1716, 17 F , H C , 183 Q ' E , , H K 4:30 . . 9, 2026 .

Corporate Governance and Other Information

I E I L P ' t C (《中華人民共和國企業所得稅法》)

Corporate Governance and Other Information

P , L

D P , C t t , , C ' t (t).

A Jt 30, 2026, 1,959,800 H t , G t .

C D , t M

O M 14, 2026, M. FANG C t .

A 2025 t Jt 30, 2026, M. E O Ft D B D C Jt 30, 2026 B D ; M . AN C Jt 30, 2026 t C .

O Jt 30, 2026, M. CHAN K t Ht - t D C .

A B D Jt 30, 2026, M t D t G M C , Jt 30, 2026.

O At t 14, 2026, M t C t .

A 2026 4, 2026, M t D B D C 4, 2026 B D .

D , t C P t .

Corporate Governance and Other Information

E P

Full Circulation of Shares

C At 21, 2025, 2, 2026, 7, 2026 27, 2026, C, C C, E C C.

9,286,359 D C H 27, 2026, H E 9:00 28, 2026. C 43,473,641 D 26,925,459 H .

Public Float

C F 5, 2026, M 2, 2026, A 9, 2026, M 7, 2026, 3, 2026 6, 2026 C ; C 27, 2026 C .

D H C E At 14, 2025, C C C ' C C At 21, 2025 C ' C 9,286,359 D H . A 4, 2025, C ' 24.11%, 25% C 19A.28B L (M P P).

26,258,059 H C 37.30% C . A . M P P 19A.28B L .

G P .

Corporate Governance and Other Information

C D ', C E ' B D

D ', 1, 2026 30, 2026 13.51B H K L :

ANG L	K H	E D	F J 22, 2017	
	M C ., L .		M 21, 2026	
	K H	M	F J 22, 2017	
	M C ., L .		M 21, 2026	
HO C	K H		F J 22, 2017	
	M C ., L .		M 21, 2026	
N	C K P		F M 29, 2026	
	H C ., L .			
	P H C ., L .	M	F 3, 2018	
			M 20, 2026	
	P H C ., L .	E D	F 3, 2018	
			M 20, 2026	

C D ', 13.51B H K L .

Corporate Governance and Other Information

D t- I

Directors', Supervisors' and Chief Executives' Interests in Securities

A J t- 30, 2026, D , t- C , t- C (P FO) C H K E t- t- D 7 8 P FO (t- / t- t- FO), C t- 352 FO, C H K E t- t- M C :

Name of Directors	Class of Shares	Nature of Interest	Number of Shares	Total Number of Shares	Approximate Percentage in Shares of the Same Class[1]	Approximate Percentage of the Company's Total Issued Share Capital[1]
M. G AN [2]	D	B B B	26 L L B B L 107 L J L B L 5.5 73 L 6 A 2.2 744309,000	7	6 412.2744309,000	(L B

Corporate Governance and Other Information

N :

(L): L

(1) 52,760,000 D 19,598,900 H (72,358,900) C 30, 2026.

(2) M. G AN M . ANG L , M . G AN D M . ANG L , M . ANG L D M. G AN P FO. M. G AN , M . ANG L M . ANG H (M . ANG L) 27,330,100 D 458,300 H C .

(3) 50% J E M C (L P) (上海金浙企業管理中心(有限合夥)) J E M C (L P) (上海金浙企業管理中心(有限合夥)) J E I P (L P). P FO, M D C .

Corporate Governance and Other Information

[illegible] 30, 2026, [illegible] B [illegible], [illegible] D [illegible], [illegible] C [illegible] C [illegible] ([illegible] P [illegible] FO) [illegible] : ( ) [illegible] C [illegible] H K E [illegible] D 7 8 P [illegible] FO ([illegible] D [illegible], [illegible] C [illegible] FO); ( ) [illegible] C [illegible] 352 FO; ( ) [illegible] C [illegible] H K E [illegible] M C [illegible].

Interests of Substantial Shareholders

A [illegible] 30, 2026, [illegible] C [illegible] 336 FO [illegible] D [illegible], [illegible] / ([illegible] D [illegible], [illegible] C) [illegible] C [illegible] H K E [illegible] D 2 3 P [illegible] FO, [illegible] 5% [illegible] C :

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class[1]	Approximate Percentage of the Company's Total Issued Share Capital[1]
C [illegible] E [illegible] I [illegible] I [illegible] F [illegible] C ., L [illegible] (中央企業鄉村產業投資基金股份有限公司)	D [illegible]	B [illegible]	7,466,666(L)	14.15%	10.32%
J E [illegible] M C [illegible] (L [illegible] P [illegible]) (上海金浙企業管理中心(有限合夥))[2]	D [illegible]	I [illegible]	4,540,000(L)	8.61%	6.27%
FAN [2]	D [illegible]	I [illegible]	4,540,000(L)	8.61%	6.27%
N J [2]	D [illegible]	I [illegible]	4,540,000(L)	8.61%	6.27%

Corporate Governance and Other Information

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class[1]	Approximate Percentage of the Company's Total Issued Share Capital[1]
J t. J t. E t. I M C ., L、. (上海金浦健服股權投資管理有限公司) [2]	D	I	4,540,000(L)	8.61%	6.27%
t. J E t. I P (L 、P) (溫州金寧股權投資合夥企業(有限合夥))	D	B	4,540,000(L)	8.61%	6.27%
[6]	D H	I t. I t.	27,330,100(L) 458,300(L)	51.80% 2.34%	37.77% 0.63%
I L.P. (上海檀英投資合夥企業(有限合夥))	D	B	4,519,003(L)	8.57%	6.25%
L I L.P. (上海樂進投資合夥企業(有限合夥)) [3]	D	I	4,519,003(L)	8.57%	6.25%
LIN L t.	D	I	5,846,364(L)	11.08%	8.08%
L I M C ., L 、 (上海正心谷投資管理有限公司) (I M C ., L、. (上海盛歌投資管理有限公司)) [4]	D	I	5,846,364(L)	11.08%	8.08%
、I C ., L、. (萬得信息技術股份有限公司)	D	I	3,333,000(L)	6.32%	4.61%
H t. t. E M C (L 、P) (上海荷花緣企業管理中心(有限合夥))	D	I	3,333,000(L)	6.32%	4.61%

Corporate Governance and Other Information

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class[1]	Approximate Percentage of the Company's Total Issued Share Capital[1]
、I E t. I (J) P (L 、P) (、I) (萬得影響力股權投資(嘉興)合夥企業(有限合夥)) (萬得投資)	D	B	3,333,000(L)	6.32%	4.61%
CI IC t. I C ., L、. (中信証券投資有限公司)	D	B	2,780,000(L)	5.27%	3.84%
CI IC t. C L 、 (中信証券股份有限公司)[5]	D	I 、	2,780,000(L)	5.27%	3.84%
O M 、A、 LLC	H	I	1,454,000(L)	7.42%	2.01%
O M 、C LLC	H	I	2,150,900(L)	10.97%	2.97%
O M 、P M F. 、L 、	H	B	1,279,900(L)	6.53%	1.77%
O M 、P II, L.P.	H	B	1,052,000(L)	5.37%	1.45%
B G t. AG	H	I 、	1,029,400(L)	5.25%	1.42%
O H	H	B	1,680,000(L)	8.57%	2.32%
ANG H t.[6]	D	B	5,785,350(L)	10.97%	8.00%
		I 、	21,544,750(L)	40.84%	29.77%
	H	B	309,000(L)	1.58%	0.43%
		I 、	149,300(L)	0.76%	0.21%
K t. H 、 L 、	H	I 、	3,114,450(L)	15.89%	4.30%
、 t. C (HK) L 、	H	t.	3,114,450(L)	15.89%	4.30%

Corporate Governance and Other Information

N :

(L): L

(1) 52,760,000 D 19,598,900 H (

Corporate Governance and Other Information

[illegible] 30, 2026, [illegible] D [illegible] ([illegible] D [illegible], [illegible] C) [illegible] C [illegible] D 2 3 P [illegible] FO, [illegible] C [illegible] 336 FO.

B [illegible] B [illegible]
Wenzhou Kangning Hospital Co., Ltd.
C [illegible]
GUAN Weili

[illegible] P C
[illegible] 21, 2026

Consolidated Balance Sheet

A 30 J 2026

(A MB)

Assets	N 4	Balance as at the end of the period	B
Current assets:			
C	4.1	312,288,962.69	294,039,860.88
P			
F	4.2	8,916,323.73	8,573,388.20
D			
N	4.3	2,102,126.86	1,486,564.55
A	4.4	400,880,378.60	462,939,569.82
A	4.5	15,647,162.19	15,792,568.62
I *			
*			
O	4.6	75,077,168.55	77,790,656.08
F			
I	4.7	43,763,736.07	46,032,543.08
I			
C			
A			
N -			
O	4.8	22,455,982.35	25,380,696.08
Total current assets		881,131,841.04	932,035,847.31

Consolidated Balance Sheet

A 30 J 2026

(A t MB t)

Assets	N 4	Balance as at the end of the period	B
Non-current assets:			
G			
D			
O			
L - t			
L - t	4.9	95,901,984.49	95,912,391.92
I t t			
O - t	4.10	23,922,657.55	28,123,065.82
I			
F	4.11	1,175,045,360.14	1,159,366,939.63
C t	4.12	18,010,945.28	13,091,854.50
P t			
O			
- t	4.13	176,805,730.32	192,354,108.23
I	4.14	256,765,010.68	285,757,258.42
I t : t			
D t			
I t : t			
G	4.15	126,454,937.63	126,454,937.63
L -	4.16	99,540,819.62	121,609,290.74
D	4.17	52,597,921.08	55,346,815.83
O - t	4.18	18,750,165.69	15,514,860.97
Total non-current assets		2,043,795,532.48	2,093,531,523.69
Total assets		2,924,927,373.52	3,025,567,371.00

L : P C A t : H A t D :
GUAN Weili JIN Hui WANG Minhui

Consolidated Balance Sheet

A 30 J 2026

(A t MB t)

Liabilities and shareholders' equity	N 4	Balance as at the end of the period	B
Current liabilities:			
-	4.20	144,675,386.56	109,243,676.71
B			
P t			
F	4.21		1,805,503.25
D			
N	4.22	26,025,756.94	
A t	4.23	123,971,726.98	160,803,092.48
	4.24	38,250,230.15	23,327,087.38
C	4.25	268,867.92	161,104.98
F t t t			
Ft			
Ft t			
E	4.26	68,352,159.50	84,431,492.90
	4.27	24,086,675.09	35,809,004.43
O	4.28	83,635,595.54	91,859,119.30
F			
L			
N - t t	4.29	254,876,060.46	201,407,509.55
O t t	4.30	1,818,258.94	3,214,866.97
Total current liabilities		765,960,718.08	712,062,457.95

Consolidated Balance Sheet

A 30 J 2026

(A t 1 1 、 MB t 1 、)

Liabilities and shareholders' equity	N 4	Balance as at the end of the period	B 、 1 t 1 、
Non-current liabilities:			
I t 1 1 *			
t 1 1 *			
L - 1 11	4.31	592,791,355.05	746,952,957.47
B 、			
I t 、 : P 1 11 、 1			
P 1 t 、			
L	4.32	134,586,128.49	148,475,651.18
L - 1	4.33	62,658,100.16	47,419,832.76
L - 1			
E 、			
D 11 、	4.34	18,054,619.00	18,206,515.00
D 11 、	4.17	30,175,216.19	40,820,058.32
O 1 - t 11			
Total non-current liabilities		838,265,418.89	1,001,875,014.73
Total liabilities		1,604,226,136.97	1,713,937,472.68

Consolidated Balance Sheet

A 30 J 2026

(A t 1 1 、 MB t 1 、)

Liabilities and shareholders' equity	N 4	Balance as at the end of the period	B 1 t 1 、
Shareholders'equity:			
1	4.35	72,358,900.00	72,358,900.00
O 1 t 1t			
I t、 : P1 11 、 1			
P 1 t 、			
C t1 t	4.36	762,132,927.31	760,645,326.71
L : 1 t1	4.37	47,815,625.17	47,815,625.17
O 1 1			
1 1			
t1 t 1 1	4.38	38,399,577.13	38,399,577.13
P1 1 1 1			
、 1	4.39	381,120,235.40	364,230,299.84
t 1 t 1 、1 1		1,206,196,014.67	1,187,818,478.51
N - 1 1		114,505,221.88	123,811,419.81
Total shareholders'equity		1,320,701,236.55	1,311,629,898.32
Total liabilities and shareholders'equity		2,924,927,373.52	3,025,567,371.00

1 1 1 .

L 1 : P1 C 1 A t : H 、 A t D 1 :
GUAN Weili JIN Hui WANG Minhui

Parent Company's Balance Sheet

A 30 J 2026

(A MB)

Assets	N 16	Balance as at the end of the period	B
Current assets:			
C		142,686,937.02	94,963,270.69
F			
D			
N			
A	16.1	35,778,993.44	36,684,264.84
A		514,070.69	1,846,331.88
O	16.2	478,250,413.79	550,863,300.90
I		9,991,932.47	10,183,513.42
I :			
C			
A			
N -			
O			
Total current assets		667,222,347.41	694,540,681.73

Parent Company's Balance Sheet

A 30 J 2026

(A MB)

Assets	N 16	Balance as at the end of the period	B
Non-current assets:			
D			
O			
L -			
L -	16.3	859,622,103.35	858,672,101.34
I			
O -		23,922,657.55	28,123,065.82
I			
F		270,487,736.88	272,207,527.96
C		1,025,192.00	1,025,192.00
P			
O			
-			
I		24,071,287.42	22,729,970.04
I			
D			
I			
G			
L -		13,345,670.23	15,910,730.63
D		20,142,255.48	18,521,653.76
O -		3,892,832.45	4,734,226.16
Total non-current assets		1,216,509,735.36	1,221,924,467.71
Total assets		1,883,732,082.77	1,916,465,149.44

L : P C A : H A D :
GUAN Weili JIN Hui WANG Minhui

Parent Company's Balance Sheet

A 30 J 2026

(A t MB t)

Liabilities and shareholders' equity	N 16	Balance as at the end of the period	B t
Current liabilities:			
-		121,000,000.00	93,720,000.00
F			
D			
N			
A t		45,779,996.59	35,437,646.63
		6,152,014.04	4,504,580.09
C			
E		16,452,808.83	20,959,095.77
		3,957,433.08	3,963,391.03
O		28,890,690.91	22,658,542.55
L			
N - t		202,883,832.00	142,430,144.00
O t			
Total current liabilities		425,116,775.45	323,673,400.07
Non-current liabilities:			
L -		224,850,000.00	379,700,000.00
B			
I t : P			
P t			
L			
L -		39,203,648.69	20,752,353.52
L -			
E			
D		7,974,619.00	8,126,515.00
D			
O - t			
Total non-current liabilities		272,028,267.69	408,578,868.52
Total liabilities		697,145,043.14	732,252,268.59

Parent Company's Balance Sheet

A 30 J 2026

(A MB)

Liabilities and shareholders' equity	N 16	Balance as at the end of the period	B
Shareholders' equity:			
		72,358,900.00	72,358,900.00
O			
I : P			
P			
C		835,335,992.58	833,848,391.98
L :		47,815,625.17	47,815,625.17
O			
		38,399,577.13	38,399,577.13
		288,308,195.09	287,421,636.91
Total shareholders' equity		1,186,587,039.63	1,184,212,880.85
Total liabilities and shareholders' equity		1,883,732,082.77	1,916,465,149.44

L : P C A : H A D :

GUAN Weili JIN Hui WANG Minhui

Consolidated Income Statement

F M E 30 J 2026

(A MB)

Item	N 4	Current period	P
I. Total revenue		829,481,414.10	738,561,625.33
I :	4.40	829,481,414.10	738,561,625.33
I			
I			
F			
II. Total cost of sales		786,080,383.38	717,628,929.06
I :	4.40	625,074,377.39	549,334,194.14
I			
F			
I			
	4.41	6,152,190.16	5,117,058.34
	4.42	3,704,122.57	3,688,280.00
G	4.43	117,409,139.69	121,819,658.37
	4.44	15,610,778.66	15,662,922.72
F	4.45	18,129,774.91	22,006,815.49
I : I		17,354,423.12	18,377,254.10
I		1,876,835.76	587,377.24
A : O	4.46	6,929,634.38	11,601,815.43
I (-)	4.47	7,047,095.81	3,832,269.03
I : I		3,177,287.11	-1,206,158.07
G			
F (-)			
G (-)			
G (-)	4.48	382,569.13	477,843.54
C (-)	4.49	-17,908,324.36	7,616,882.44
A (-)			
G (-)	4.50	46,657.62	1,250,151.08

Consolidated Income Statement

F M E 30 J 2026

(A MB)

Item	N 4	Current period	P
III. Operating profits (losses represented with “-” sign)		39,898,663.30	45,711,657.79
A :	4.51	1,790,407.41	66,456.85
L : -	4.52	17,974,248.24	3,798,544.46
IV. Total profits (total losses represented with “-” signs)		23,714,822.47	41,979,570.18
L :	4.53	1,527,631.84	15,210,452.03
V. Net profit (net losses represented with “-” signs)		22,187,190.63	26,769,118.15
(I) C			

Consolidated Income Statement

F M E 30 J 2026

(A MB)

Item	N 4	Current period	P
(II) O			
1. O			
2. C			
3. A			
4. C			
5.			
6. E			
7. F			
8. F			
9. O			
O - ,			
VII. Total comprehensive income		22,187,190.63	26,769,118.15
A		33,773,135.56	36,530,359.57
A -		-11,585,944.93	-9,761,241.42
VIII. Earnings per share:			
(I) B (MB/)	4.54	0.48	0.50
(II) D (MB/)	4.54	0.48	0.50

.

L :	P C A :	H A D :
GUAN Weili	JIN Hui	WANG Minhui

Parent Company's Income Statement

F M E 30 J 2026

(A MB)

Item	N 16	Amount for the current period	A
I. Revenue	16.4	188,739,211.50	191,631,445.80
L : C	16.4	126,878,067.39	128,370,674.76
		1,655,027.16	2,561,069.88
		371,907.53	90,226.09
G		34,121,985.20	38,256,463.25
		11,908,768.61	11,922,725.70
F		3,513,709.22	4,120,776.89
I : I		8,654,328.52	9,614,227.57
I		6,495,030.71	7,236,569.03
A : O		4,949,365.04	2,672,633.24
I (-)	16.5	5,520,759.22	1,526,125.08
I : I		520,759.22	1,526,125.08
D			
G			
(-)			
G			
(-)		39,633.60	49,582.16
C			
(-)		-4,545,659.64	1,715,895.58
A			
(-)			
G			
(-)			
II. Operating profits (losses represented with "-" signs)		16,253,844.61	12,273,745.29
A :		198,725.12	600.00
L : -		303,413.27	149,905.92
III. Total profits (losses represented with "-" signs)		16,149,156.46	12,124,439.37
L :		-1,620,601.72	1,727,950.25
IV. Net profit (losses represented with "-" signs)		17,769,758.18	10,396,489.12
(I) N (-)		17,769,758.18	10,396,489.12
(II) N (-)			

Parent Company's Income Statement

F M E 30 J 2026

(A MB)

Item	N 16	Amount for the current period	A
V. Other comprehensive income, net of tax			
(I) O			
1. C			
2. O			
3. C			
4. C			
5. O			
(II) O			
1. O			
2. C			
3. A			
4. C			
5.			
6. E			
7. O			
VI. Total comprehensive income		17,769,758.18	10,396,489.12
VII. Earnings per share:			
(I) B (MB/)			
(II) D (MB/)			

L : P C A : H A D :
GUAN Weili JIN Hui WANG Minhui

Consolidated Statement of Cash Flows

F M E 30 2026

(A MB)

Item	3 N N 4	Amount for the current period A 96 2 4
I. Cash flows from operating activities		

Consolidated Statement of Cash Flows

F M E 30 J 2026

(A MB)

Item	N 4	Amount for the current period	A
IV. Effect of foreign exchange rate changes on cash and cash equivalents		-73,292.86	-2,486.65
V. Net increase in cash and cash equivalents		23,239,882.63	77,873,891.63
A : C	4.55	287,672,625.54	255,232,744.16
VI. Cash and cash equivalents at the end of the period	4.55	310,912,508.17	333,106,635.79

L : P C A : H A D :

GUAN Weili JIN Hui WANG Minhui

Parent Company's Statement of Cash Flows

F M E 30 J 2026

(A MB)

Item	N	Amount for the current period	A
I. Cash flows from operating activities			
C		191,543,146.34	204,706,377.93
C		226,428,000.07	223,954,868.42
Sub-total of cash inflows of operating activities		417,971,146.41	428,661,246.35
C		59,470,750.21	73,535,871.41
C		85,396,690.05	92,633,698.18
C		3,966,870.24	3,772,451.41
C		145,508,480.55	192,295,435.48
Sub-total of cash outflows of operating activities		294,342,791.05	362,237,456.48
Net cash flows from operating activities		123,628,355.36	66,423,789.87
II. Cash flows from investing activities			
C		4,495,041.87	
C		12,500,000.00	
N		23,264.00	2,832.00
C			
Sub-total of cash inflows of investing activities		17,018,305.87	2,832.00
C		1,594,731.65	5,284,196.52
C			9,000,000.00
N			
C			
Sub-total of cash outflows of investing activities		1,594,731.65	14,284,196.52
Net cash flows from investing activities		15,423,574.22	-14,281,364.52

Parent Company's Statement of Cash Flows

F M E 30 J 2026

(A MB)

Item	N	Amount for the current period	A
III. Cash flows from financing activities			
C			
C		181,000,000.00	113,720,000.00
C		26,524,880.00	
Sub-total of cash inflows of financing activities		207,524,880.00	113,720,000.00
C		248,320,000.00	117,350,000.00
C		25,537,528.52	11,533,957.02
C		24,922,666.96	16,069,212.44
Sub-total of cash outflows of financing activities		298,780,195.48	144,953,169.46
Net cash flows from financing activities		-91,255,315.48	-31,233,169.46
IV. Effect of foreign exchange rate changes on cash and cash equivalents		-73,292.86	-2,486.65
V. Net increase in cash and cash equivalents		47,723,321.24	20,906,769.24
A : C		93,598,161.26	110,788,421.25
VI. Cash and cash equivalents at the end of the period		141,321,482.50	131,695,190.49

L : P C A : H A D :
GUAN Weili JIN Hui WANG Minhui

Consolidated Statement of Changes in Shareholders' Equity

F M E 30 J 2026

(A MB)

Item	Amount for the current period												
	Equity attributable to owners of the parent company												
		Other equity instruments											
	Share capital	Preferred shares	Perpetual bonds	Others	Capital reserves	Less: treasury stocks	Other comprehensive income	Special reserves	Surplus reserves	Provision for general risk	Retained earnings	Subtotal	Minority equity	Total shareholders' equity
I. Balance as at the end of the previous year	72,358,900.00				780,645,326.71	47,815,625.17			38,399,577.13		384,230,299.84	1,187,818,478.51	123,811,419.81	1,311,629,898.32
A.														
C														
B														
O														
II. Balance as at the beginning of the current year	72,358,900.00				780,645,326.71	47,815,625.17			38,399,577.13		384,230,299.84	1,187,818,478.51	123,811,419.81	1,311,629,898.32
III. Increases/decreases in the current period ("-" for decreases)					1,487,600.60						16,889,935.56	18,377,536.16	-9,306,197.93	9,071,338.23
(I)											33,773,135.56	33,773,135.56	-11,585,944.93	22,187,190.63
(II) C					1,487,600.60							1,487,600.60	1,913,494.00	3,401,094.60
1. C													1,913,494.00	1,913,494.00
2. C														
3. A					1,487,600.60							1,487,600.60		1,487,600.60
4. O														
(III) P											-16,883,200.00	-16,883,200.00	366,253.00	-16,516,947.00
1.														
2.														
3. P											-16,883,200.00	-16,883,200.00	366,253.00	-16,516,947.00
4. O														
(IV) I														
1. C														
2. C														
3.														
4. C														
5. C														
6. O														
(V)														
1.														
2.														
(VI) O														
IV. Balance as at the end of the current period	72,358,900.00				782,132,927.31	47,815,625.17			38,399,577.13		381,120,235.40	1,206,196,014.67	114,505,221.88	1,320,701,236.55

L : P C A : H A D :

GUAN Weili JIN Hui WANG Minhui

Consolidated Statement of Changes in Shareholders' Equity

F M E 30 J 2026

(A MB)

I	A	E	O	L	P	M	T
I. Balance as at the end of the previous year	72,670,000.00	790,024,238.03	22,366,848.64	38,399,577.13	344,285,828.01	120,288,896.30	1,343,301,690.83
A :							
C							
B							
O							
II. Balance as at the beginning of the current year	72,670,000.00	790,024,238.03	22,366,848.64	38,399,577.13	344,285,828.01	120,288,896.30	1,343,301,690.83
III. Increases/decreases in the current period ("-" for decreases)	-311,100.00	-107,455.91			14,729,359.57	14,310,803.66	2,664,714.73	16,975,518.39
(I)					36,530,359.57	36,530,359.57	-9,761,241.42	26,769,118.15
(II) C	-311,100.00	-107,455.91				-418,555.91	12,425,956.15	12,007,400.24
1. C	-311,100.00	-2,939,298.96				-3,250,398.96	12,425,956.15	9,175,557.19
2. C								
3. A		2,831,843.05				2,831,843.05		2,831,843.05
4. O								
(III) P					-21,801,000.00	-21,801,000.00		-21,801,000.00
1.								
2.								
3. P					-21,801,000.00	-21,801,000.00		-21,801,000.00
4. O								
(I) I								
1. C								
2. C								
3.								
4. C								
5. C								
6. O								
( )								
1.								
2.								
(I) O								
IV. Balance as at the end of the current period	72,358,900.00	789,916,782.12	22,366,848.64	38,399,577.13	359,015,187.58	1,237,323,598.19	122,953,611.03	1,360,277,209.22

L : P C A : H A D :

GUAN Weili JIN Hui WANG Minhui

Parent Company’s Statement of Changes in Shareholders’ Equity

F M E 30 J 2026

(A MB)

Item	Amount for the current period										
	Other equity instruments										
	Share capital	Preferred shares	Perpetual bonds	Others	Capital reserves	Less: treasury stocks	Other comprehensive income	Special reserves	Surplus reserves	Retained earnings	Total shareholders’ equity
I. Balance as at the end of the previous year	72,359,900.00				833,849,391.98	47,815,625.17			38,399,577.13	287,421,636.91	1,184,212,880.85
A.											
C											
O											
II. Balance as at the beginning of the current year	72,359,900.00				833,849,391.98	47,815,625.17			38,399,577.13	287,421,636.91	1,184,212,880.85
III. Increases/decreases in the current period (“-” for decreases)					1,487,600.60					886,558.18	2,374,158.78
(I)										17,769,758.18	17,769,758.18
(II) C					1,487,600.60						1,487,600.60
1. C											
2. C											
3. A					1,487,600.60						1,487,600.60
4. O											
(III) P										-16,883,200.00	-16,883,200.00
1.											
2. P											
3. O											
(I) I										-16,883,200.00	-16,883,200.00
1. C											
2. C											
3.											
4. C											
5. C											
6. O											
( )											
1.											
2.											
( ) O											

Parent Company's Statement of Changes in Shareholders' Equity

F M E , 30 J 2026

(A MB)

I	A	O								
		P	P	O	C	L	O			
I. Balance as at the end of the previous year	72,670,000.00				832,320,975.11	22,366,848.64		38,399,577.13	288,933,417.68	1,209,957,121.28
A :										
C										
O										
II. Balance as at the beginning of the current year	72,670,000.00				832,320,975.11	22,366,848.64		38,399,577.13	288,933,417.68	1,209,957,121.28
III. Increases/decreases in the current period ("-" for)	-311,100.00				-143,665.74				-11,404,510.88	-11,859,276.62
(I)									10,396,489.12	10,396,489.12
(II) C	-311,100.00				-143,665.74					-454,765.74
1. C	-311,100.00				-2,939,298.96					-3,250,398.96
2. C										
3. A					2,795,633.22					2,795,633.22
4. O										
(III) P									-21,801,000.00	-21,801,000.00
1.										
2. P									-21,801,000.00	-21,801,000.00
3. O										
(I) I										
1. C										
2. C										
3.										
4. C										
5. C										
6. O										
( )										
1.										
2.										
(I) O										
IV. Balance as at the end of the current period	72,358,900.00				832,177,309.37	22,366,848.64		38,399,577.13	277,528,906.80	1,198,097,844.66

L : P C A : H A D :

GUAN Weili JIN Hui WANG Minhui

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

1 C

K H C ., L . (C G) H P C F 1996. C D , P C.

O 15 O 2014, C K H C ., L .

C E H K L 20 N 2015. C

A 30 J 2026, C 72,358,900 C MB72,358,900.

D , P C, D , P C.

C G L .

O 21 2026, B D C .

Notes to the Financial Statements

F M E 30 J 2026
(A MB)

2 B

2.1 Basis for preparation

A B E B , A B E A G , A B E I (, A B E) M F , G L E H K L , H K C O .

A B E N . 32 I F M F .

G ' 2025. G 2025.

2.2 Going concern

.

2.3 Statement of compliance with the Accounting Standards for Business Enterprises

A B E M F , C 30 J 2026, 30 J 2026.

Notes to the Financial Statements

F M E 30 2026

(A MB)

3

3.1 Main tax types and tax rates

Tax type	Basis of tax assessment	Tax rate
		3%, 6%, 13%
C	B	7%
E	B	5%
P	70% 1.2% 12%	
E	B	15%, 20%, 25%
N		

Taxpayer		Income tax rate
	K H C ., L .	15%
	J H C ., L .	15%
	K F C	20%
H	C H C ., L .	20%
	D C C ., L .	20%
	D N C ., L .	20%
	D C C ., L .	20%
	D E C ., L .	20%

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

3 (C)

3.2 Tax preferences

1. P C O P P L A P B (C 2016 N . 36) M F A C M I (O C N . 149) C I M A M M I (O M H N . 35) M H M I P L .

2. P P K F C , A 3%.

3. P M I P P L A P B (C 2016 N . 36) M F A P C A 6% 3%.

4. C H - E C (N . G 202433013060) D P , 3 A 28 E I L P C , C 15% 1 J 2025 31 D 2027.

5. O 8 D 2023, J H C ., L ., C , H - E C (N . G 202333001809) D P , 3 A 28 E I L P C , 15% 1 J 2023 31 D 2026.

Notes to the Financial Statements

F M E 30 2026
(A MB)

3 (C)

3.2 Tax preferences *(Continued)*

6. A A M F A
P P M E I I I C H (A M F
A 2023 N .6), - , 25%,
MB1 20%.

4 N

N : B 31 D 2025 ( ), 30 2026 ( ), 30 2026 ( ), 30 2025 ( ).

4.1 Cash at bank and on hand

Item	Balance as at the end of the period	B
C	239,908.03	231,487.96
B	311,069,596.19	287,835,608.12
O	979,458.47	5,972,764.80
	312,288,962.69	294,039,860.88

O :

A 30 2026, C MB1,376,454.52, E C , N 4.19.

Notes to the Financial Statements

F M E 30 2026

(A MB)

4 N (C)

4.2 Financial assets held for trading

Item	Balance as at the end of the period	B
F		
	8,916,323.73	8,573,388.20
I :	8,916,323.73	8,573,388.20
	8,916,323.73	8,573,388.20

4.3 Notes receivable

4.3.1 P

Item	Balance as at the end of the period	B
B	2,102,126.86	1,486,564.55
	2,102,126.86	1,486,564.55

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.3 Notes receivable *(Continued)*

4.3.2 D

	Balance as at the end of the period					B			
	Book balance		Provision for bad debts			B		P	
Category	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value	A	P (%)	A	P (%) B
P									
	2,102,126.86	100.00			2,102,126.86	1,486,564.55	100.00		1,486,564.55
I :									
P									
	2,102,126.86	100.00			2,102,126.86	1,486,564.55	100.00		1,486,564.55
	2,102,126.86	100.00			2,102,126.86	1,486,564.55	100.00		1,486,564.55

P :

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.3 Notes receivable *(Continued)*

4.3.2 D (C)

I :

Name	Balance as at the end of the period		
	Notes receivable	Provision for bad debts	Proportion of provision (%)
P	2,102,126.86		
	2,102,126.86		

4.3.3 A C

4.3.4 A C

Item	Amount derecognised as at the end of the period	A
B		1,802,126.86
		1,802,126.86

4.3.5

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.4 Accounts receivable

4.4.1 D

Aging	Balance as at the end of the period	B
1 (1)	401,958,284.54	461,352,554.54
1 2	26,119,529.25	25,588,614.28
2 3	10,656,739.75	8,844,667.79
O 3	7,248,551.51	7,368,906.35
-	445,983,105.05	503,154,742.96
L :	45,102,726.45	40,215,173.14
	400,880,378.60	462,939,569.82

C

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.4 Accounts receivable *(Continued)*

4.4.2 D

	Balance as at the end of the period					B			
	Book balance		Provision for bad debts			B		P	
Type	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value	A	P (%)	A	P (%)	B
P										
	25,662,713.50	5.75	19,530,306.20	76.10	6,132,407.30	15,171,843.80	3.02	15,171,843.80	100.00	
I :										
M	25,662,713.50	5.75	19,530,306.20	76.10	6,132,407.30	15,171,843.80	3.02	15,171,843.80	100.00	
P										
	420,320,391.55	94.25	25,572,420.25	6.08	394,747,971.30	487,982,899.16	96.98	25,043,329.34	5.13	462,939,569.82
I :										
P	420,320,391.55	94.25	25,572,420.25	6.08	394,747,971.30	487,982,899.16	96.98	25,043,329.34	5.13	462,939,569.82
	445,983,105.05	100.00	45,102,726.45	/	400,880,378.60	503,154,742.96	100.00	40,215,173.14	/	462,939,569.82

:

	Balance as at the end of the period				B	
Name	Book balance	Provision for bad debts	Proportion of provision (%)	Basis of provision	B	P
M	25,662,713.50	19,530,306.20	76.10	Provision for bad debts for lifetime expected credit loss	15,171,843.80	15,171,843.80
	25,662,713.50	19,530,306.20	/	/	15,171,843.80	15,171,843.80

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.4 Accounts receivable *(Continued)*

4.4.2 D (C)

P :

I :

Name	Balance as at the end of the period		
	Accounts receivable	Provision for bad debts	Proportion of provision (%)
P	420,320,391.55	25,572,420.25	6.08
	420,320,391.55	25,572,420.25	/

4.4.3 P

Type	B	Changes in the current period				Balance as at the end of the period
		Provision	Recovery or reversal	Written-back or written-off	Other changes	
P	15,171,843.80	18,017,650.91		13,659,188.51		19,530,306.20
P	25,043,329.34	529,090.91				25,572,420.25
	40,215,173.14	18,546,741.82		13,659,188.51		45,102,726.45

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.4 Accounts receivable *(Continued)*

4.4.4 A

Item	Charge-off amount
A	604,568.51

4.5 Advances to suppliers

P

	Balance as at the end of the period		B	
Aging	Amount	Proportion (%)	A	P (%)
1	15,646,935.50	100.00	15,788,868.62	99.98
1-2	226.69		3,700.00	0.02
	15,647,162.19	100.00	15,792,568.62	100.00

4.6 Other receivables

Item	Balance as at the end of the period	B
I		787,500.00
O	75,077,168.55	77,003,156.08
	75,077,168.55	77,790,656.08

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.6 Other receivables *(Continued)*

4.6.1 I

(1) C

Item	Balance as at the end of the period	B
		787,500.00
-		787,500.00
L :		
		787,500.00

4.6.2 O

(1) D

Aging	Balance as at the end of the period	B
1 (1)	38,835,165.68	4,457,721.23
1 2	4,124,932.40	22,576,274.23
2 3	8,852,533.24	45,220,543.09
3 4	23,810,754.65	3,648,182.82
4 5	3,038,043.54	8,293,985.49
O 5	11,910,414.31	9,073,199.23
-	90,571,843.82	93,269,906.09
L :	15,494,675.27	16,266,750.01
	75,077,168.55	77,003,156.08

C

Notes to the Financial Statements

F M E 30 2026

(A MB)

4 N (C)

4.6 Other receivables *(Continued)*

4.6.2 O (C)

(2) D

	Balance as at the end of the period					B				
	Book balance		Provision for bad debts			B		P		
Category	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value	A	P (%)	A	P (%)	B
P										
	13,694,758.77	15.12	13,694,758.77	100.00		14,273,961.68	15.30	14,273,961.68	100.00	
I :										
Q D										
H C., L.						579,202.91	0.62	579,202.91	100.00	
H										
P										
C., L.	10,204,311.69	11.27	10,204,311.69	100.00		10,204,311.69	10.94	10,204,311.69	100.00	
C	3,490,447.08	3.85	3,490,447.08	100.00		3,490,447.08	3.74	3,490,447.08	100.00	
P										
	76,877,085.05	84.88	1,799,916.50	2.34	75,077,168.55	78,995,944.41	84.70	1,992,788.33	2.52	77,003,156.08
I :										
C										
	76,877,085.05	84.88	1,799,916.50	2.34	75,077,168.55	78,995,944.41	84.70	1,992,788.33	2.52	77,003,156.08
	90,571,843.82	100.00	15,494,675.27	/	75,077,168.55	93,269,906.09	100.00	16,266,750.01	/	77,003,156.08

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.6 Other receivables *(Continued)*

4.6.2 O (C)

(2) D (C)

:

Name	Balance as at the end of the period				B	
	Book balance	Provision for bad debts	Proportion of provision (%)	Basis of provision	B	P
H P C., L.	10,204,311.69	10,204,311.69	100.00	Expected to be difficult to recover	10,204,311.69	10,204,311.69
C	3,490,447.08	3,490,447.08	100.00	Expected to be difficult to recover	3,490,447.08	3,490,447.08
	13,694,758.77	13,694,758.77	/	/	13,694,758.77	13,694,758.77

P :

I :

Name	Balance as at the end of the period		
	Other receivables	Provision for bad debts	Proportion of provision (%)
C	76,877,085.05	1,799,916.50	2.34
	76,877,085.05	1,799,916.50	/

Notes to the Financial Statements

F M E 30 2026

(A MB)

4 N (C)

4.6 Other receivables *(Continued)*

4.6.2 O (C)

(3) I :

Provision for bad debts	Stage I Expected credit loss in the next 12 months	Stage II Lifetime expected credit loss (without credit impairment)	Stage III Lifetime expected credit loss (with credit impairment)	Total
B				
	1,992,788.33		14,273,961.68	16,266,750.01
I				
		II		
		III		
		II		
		I		
P				
	59,214.55		579,202.91	638,417.46
	123,657.28			123,657.28
	10,000.00			10,000.00
O				
B				
	1,799,916.50		13,694,758.77	15,494,675.27

Notes to the Financial Statements

F M E 30 2026

(A MB)

4 N (C)

4.7 Inventories

	Balance as at the end of the period			B	B
Category	Book balance	Provision for inventory depreciation/ Provision for impairment of contract performance cost	Book value	B	B
	424,994.90		424,994.90	567,310.08	567,310.08
	40,884,690.50		40,884,690.50	45,089,109.86	45,089,109.86
C	2,454,050.67		2,454,050.67	376,123.14	376,123.14
	43,763,736.07		43,763,736.07	46,032,543.08	46,032,543.08

4.8 Other current assets

Item	Balance as at the end of the period	B
I	21,909,074.61	23,120,442.10
E		12,210.28
D	546,907.74	2,248,043.70
	22,455,982.35	25,380,696.08

Notes to the Financial Statements

F M E 30 J 2026
(A MB)

4 N (C)

4.9 Long-term equity investments

4.9.1 D -

Investee	B (B)	B	Increase/decrease in current period: Additional investment	Reduced investment	Profit or loss on investments recognised under the equity method	Adjustment to other comprehensive income	Changes in other equity	Cash dividends or profits declared to be distributed	Provision for impairment	Others	Balance as at the end of the period (Book value)	Balance of provision for impairment as at the end of the period
H A M C., L.	9,316,664.65				831,424.73						10,148,089.38	
L H C., L.	56,002,864.79				-310,665.51						55,692,199.28	
H M C C., L.	20,891,659.34				-1,134,399.41						19,757,259.93	
C H K H C., L.	831,375.76	5,983,353.47		9,852,000.00	4,049,205.94				-5,864,305.45		892,887.16	119,048.02
F N C., L.	4,552,518.81				-101,568.88						4,450,949.93	
O H M C., L.	4,317,308.57		800,000.00		-156,709.76						4,960,598.81	
H M H M C., L.												
	95,912,391.92	5,983,353.47	800,000.00	9,852,000.00	3,177,287.11				-5,864,305.45		95,901,984.49	119,048.02

O :

1、 I M 2026, C H K H C., L., C MB9,852,000.00 40%, MB9,852,000.00 MB5,864,305.45 .

2、 I F 2026, C - MB800,000.00 O H M C., L..

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.9 Long-term equity investments *(Continued)*

4.9.2 I -

I C H K

H C ., L .,

MB119,048.02.

4.10 Other non-current financial assets

Item	Balance as at the end of the period	B
F		
	23,922,657.55	28,123,065.82
I :	23,922,657.55	28,123,065.82
	23,922,657.55	28,123,065.82

4.11 Fixed assets

4.11.1 F

Item	Balance as at the end of the period	B
F	1,175,045,360.14	1,159,366,939.63
D		
	1,175,045,360.14	1,159,366,939.63

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.11 Fixed assets *(Continued)*

4.11.2 B

Item	Buildings and constructions	Medical equipment	Transportation facilities	Electronic and other equipment	Fixed assets acquired under leaseback after sale and finance lease	Total
1. O						
(1) B						
	1,285,625,134.84	89,677,614.58	14,444,580.86	83,989,797.49	90,666,399.96	**1,564,403,527.73**
(2) I	31,704,931.89	10,289,149.00	484,858.41	3,465,313.34	7,002,753.60	**52,947,006.24**
P	18,958,386.11	10,289,149.00	484,858.41	3,465,313.34		**33,197,706.86**
	7,750,450.31					**7,750,450.31**
O	4,996,095.47				7,002,753.60	**11,998,849.07**
(3) D	1,728,000.00	11,054,794.94	592,659.00	2,118,470.61	4,705,176.60	**20,199,101.15**
D		7,429,705.54	592,659.00	1,150,386.55	3,436,420.00	**12,609,171.09**
O	1,728,000.00	3,625,089.40		968,084.06	1,268,756.60	**7,589,930.06**
(4) B	1,315,602,066.73	88,911,968.64	14,336,780.27	85,336,640.22	92,963,976.96	**1,597,151,432.82**
2. A						
(1) B						
	190,782,813.67	71,665,898.55	11,600,666.92	68,004,376.89	62,982,832.07	**405,036,588.10**
(2) I	19,489,949.91	4,887,216.64	663,864.16	4,459,533.25	4,949,666.53	**34,450,230.49**
P	18,643,498.07	4,487,710.28	663,864.16	4,459,533.25	4,949,666.53	**33,204,272.29**
O	846,451.84	399,506.36				**1,245,958.20**
(3) D	23,451.43	10,930,797.63	593,034.67	2,094,287.43	3,739,174.75	**17,380,745.91**
D		7,292,359.70	567,798.46	1,117,078.69	3,344,235.00	**12,321,471.85**
O	23,451.43	3,638,437.93	25,236.21	977,208.74	394,939.75	**5,059,274.06**
(4) B	210,249,312.15	65,622,317.56	11,671,496.41	70,369,622.71	64,193,323.85	**422,106,072.68**
3. P						
(1) B						
(2) I						
(3) D						
(4) B						
4. B						
(1) B						
	1,105,352,754.58	23,289,651.08	2,665,283.86	14,967,017.51	28,770,653.11	

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.12 Construction in progress

4.12.1 C

Item	Balance as at the end of the period			B			
	Book balance	Provision for impairment	Book value	B	P	B	
C P	18,010,945.28		18,010,945.28	13,091,854.50		13,091,854.50	
	18,010,945.28		18,010,945.28	13,091,854.50		13,091,854.50	

4.12.2 D

Item	Balance as at the end of the period			B			
	Book balance	Provision for impairment	Book value	B	P	B	
L K H	1,244,336.00		1,244,336.00	1,135,716.00		1,135,716.00	
K H	1,025,192.00		1,025,192.00	911,592.00		911,592.00	
C H	3,174,380.65		3,174,380.65	1,756,128.00		1,756,128.00	
H	3,352,254.64		3,352,254.64	2,497,808.10		2,497,808.10	
C H	5,049,131.00		5,049,131.00	5,045,131.00		5,045,131.00	
L C H	4,039,650.99		4,039,650.99				
O	126,000.00		126,000.00	1,745,479.40		1,745,479.40	
	18,010,945.28		18,010,945.28	13,091,854.50		13,091,854.50	

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.12 Construction in progress *(Continued)*

4.12.3 C

Project name	Budget (RMB '0,000)	B	Increase in current period	Amount transferred to fixed assets in current period	Other decreases in current period	Balance as at the end of the period	Proportion of accumulated project investment in budget (%)	Project progress (%)	Accumulated capitalised amount of interest	Including: capitalization amount of interest in current period	Capitalization rate of interest in current period (%)	
C H	833.60	5,045,131.00	4,000.00			5,049,131.00	60.52	60.00				Self-owned funds
L C H	711.00		4,039,650.99			4,039,650.99	56.82	60.00				Self-owned funds
	/	5,045,131.00	4,043,650.99			9,088,781.99	/	/				

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.14 Intangible assets

Item	Land use right	Trademark right	Software	Medical practicing qualification	Contractual right to provide management services	Total
1. O						
(1) B						
	163,459,981.01	3,061,637.13	21,903,480.22	240,837,000.00	32,400,000.00	461,662,098.36
(2) I	3,748,571.32		3,016,152.39			6,764,723.71
P			3,016,152.39			3,016,152.39
O	3,748,571.32					3,748,571.32
(3) D			5,704,571.32		30,000,000.00	35,704,571.32
D			1,956,000.00		30,000,000.00	31,956,000.00
O			3,748,571.32			3,748,571.32
(4) B						
	167,208,552.33	**3,061,637.13**	**19,215,061.29**	**240,837,000.00**	**2,400,000.00**	**432,722,250.75**
2. A						
(1) B						
	26,587,032.78	1,734,910.61	12,666,032.28	106,649,007.03	14,267,857.20	161,904,839.90
(2) I	1,805,986.73	165,007.68	721,278.82	11,611,873.83	239,285.72	14,543,432.78
P	1,805,986.73	165,007.68	721,278.82	11,611,873.83	239,285.72	14,543,432.78
(3) D			1,241,032.65		13,250,000.00	14,491,032.65
D			1,241,032.65		13,250,000.00	14,491,032.65
(4) B						
	28,393,019.51	**1,899,918.29**	**12,146,278.45**	**118,260,880.86**	**1,257,142.92**	**161,957,240.03**
3. P						
(1) B						
				14,000,000.04		14,000,000.04
(2) I						
(3) D						
(4) B						
				14,000,000.04		**14,000,000.04**
4. B						
(1) B						
	138,815,532.82	**1,161,718.84**	**7,068,782.84**	**108,576,119.10**	**1,142,857.08**	**256,765,010.68**
(2) B						
	136,872,948.23	1,326,726.52	9,237,447.94	120,187,992.93	18,132,142.80	285,757,258.42

O :

A 30 J 2026, MB89,344,625.89 N 4.19 .

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.15 Goodwill

4.15.1 C

Name of the investee or matters forming goodwill	Balance as at the end of the previous year	Increase in the current period: Amount formed through business combination	Increase in the current period: Others	Decrease in the current period: Disposal	Decrease in the current period: Others	Balance as at the end of the period
O						
N H C., L.	9,271,800.00					9,271,800.00
H P H C., L.	690,331.47					690,331.47
G H C., L.	1,549,022.38					1,549,022.38
N P H C., L.	7,784,850.00					7,784,850.00
B H C., L.	22,987,331.04					22,987,331.04
H C., L.	151,048.40					151,048.40
H K H C., L.	5,068,959.78					5,068,959.78
C K P H C., L.	6,843,288.91					6,843,288.91
C H C., L.	19,416,285.97					19,416,285.97
P C H C., L.	51,770,194.67					51,770,194.67
H N C., L.	1,272,643.00					1,272,643.00
J H C., L.	5,060,323.85					5,060,323.85
L C K K H C., L.	283,528.10					283,528.10
D L H C., L.	2,502,854.13					2,502,854.13
C J P H C., L.	9,564,442.65					9,564,442.65
H H C., L.	12,898,816.77					12,898,816.77
D C C., L.	11,081,970.63					11,081,970.63
-	168,197,691.75					168,197,691.75
P						
B H C., L.	22,987,331.04					22,987,331.04
G H C., L.	1,549,022.38					1,549,022.38
J H C., L.	5,060,323.85					5,060,323.85
H P H C., L.	690,331.47					690,331.47
D L H C., L.	2,502,854.13					2,502,854.13
N P H C., L.	7,705,714.73					7,705,714.73
H N C., L.	1,247,176.52					1,247,176.52
-	41,742,754.12					41,742,754.12
B	126,454,937.63					126,454,937.63

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.15 Goodwill *(Continued)*

4.15.2 C

Name	Composition and basis of the asset group or combination of asset groups	Whether it is consistent with the previous years
N H C., L.	A	C
H P H C., L.	A	C
G H C., L.	A	C
N P A H C., L.	A	C
B H C., L.	A	C
H C., L.	A	C
H K H C., L.	A	C
C K P A H C., L.	A	C
C H C., L.	A	C
P C H A C., L.	A	C
H N C., L.	A	C
J H C., L.	A	C
L C K K H A C., L.	A	C
D L H C., L.	A	C
C J P A H C., L.	A	C
H H C., L.	A	C
D C C., L.	A	C

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.15 Goodwill *(Continued)*

4.15.3

:

Item	Book value	Recoverable amount	Amount of impairment (Notes:)	Years of the forecast period	Key parameters (growth rate, profit margin, etc.) during the forecast period	Determination basis of the key parameters during the forecast period	Key parameters (growth rate, profit margin, discount rate, etc.) during the stabilization period	Determination basis of the key parameters during the stabilization period
N H C ., L. .	27,409,156.22	36,000,000.00		5	N 4.15.4 K	H	2.10%	B 5-
N P H C ., L. .	5,369,459.16	6,000,000.00		5	N 4.15.4 K	H	2.10%	B 5-
K H C ., L. .	10,915,345.65	20,000,000.00		5	N 4.15.4 K	H	2.20%	B 5-
C K P H C ., L. .	19,346,122.81	38,000,000.00		5	N 4.15.4 K	H	2.10%	B 5-
C H C ., L. .	43,740,349.95	74,000,000.00		5	N 4.15.4 K	H	2.20%	B 5-
P C H C ., L. .	149,712,997.39	188,000,000.00		5	N 4.15.4 K	H	2.20%	B 5-

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.15 Goodwill *(Continued)*

4.15.3 (C)

: (C)

Item	Book value	Recoverable amount	Amount of impairment (Notes:)	Years of the forecast period	Key parameters (growth rate, profit margin, etc.) during the forecast period	Determination basis of the key parameters during the forecast period	Key parameters (growth rate, profit margin, discount rate, etc.) during the stabilization period	Determination basis of the key parameters during the stabilization period
H N C., L.	1,201,035.69	1,300,000.00		5	N 4.15.4 K	H	2.20%	B 5-
D L H C., L.	3,786,855.48	5,000,000.00		5	N 4.15.4 K	H	2.10%	B 5-
C J P H C., L.	46,942,654.65	54,000,000.00		5	N 4.15.4 K	H	2.10%	B 5-
H H C., L.	84,221,585.08	93,100,000.00		5	N 4.15.4 K	H	2.10%	B 5-
D C C., L.	12,546,488.99	28,000,000.00		5	N 4.15.4 K	H	2.10%	B 5-
	405,192,051.06	543,400,000.00		/	/	/	/	

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.15 Goodwill *(Continued)*

4.15.4 K

Asset group or combination of asset groups	Average number of beds in operation	Key parameters of forecast period: Average daily cost per bed for inpatients (bed/day/RMB)	Net profit margin	Pre-tax discount rate
N H C ., L .	147	315	16.34%	10.40%
H C ., L .	172	563	6.29%	10.40%
N P H C ., L .	243	215	2.90%	12.10%
H K H C ., L .	180	179	15.36%	12.10%
C K P H C ., L .	323	193	13.55%	12.10%
C H C ., L .	330	534	10.57%	11.30%
P C H C ., L .	594	556	8.05%	10.40%
H N C ., L .	56	118	-3.06%	10.40%
D L H C ., L .	224	112	-12.01%	12.10%
C J P H C ., L .	306	207	7.27%	10.40%
D C C ., L .	1,360 (N)	97		13.67%

N :

D C C ., L . , , .

4.15.5 C

Item	Completion of performance commitments: The current period: Committed performance	The current period: Actual performance	The current period: Completion rate	The previous period: Committed performance	The previous period: Actual performance	The previous period: Completion rate	Accrued goodwill impairment loss: The current period	Accrued goodwill impairment loss: The previous period
D C C ., L .				3,240,000.00	3,601,100.65	111.15%		

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.16 Long-term prepaid expenses

Item	B	Increase in current period	Amortisation in current period	O	Balance as at the end of the period
	121,496,442.87	2,662,387.01	19,721,849.52	4,996,095.47	99,440,884.89
	112,847.87		12,913.14		99,934.73
	121,609,290.74	2,662,387.01	19,734,762.66	4,996,095.47	99,540,819.62

4.17 Deferred tax assets and deferred tax liabilities

4.17.1 D

Item	Balance as at the end of the period		B	
	Deductible temporary differences	Deferred tax assets	D	D
A	44,044,318.91	9,595,760.87	30,120,762.75	6,119,599.81
	27,750,762.85	6,937,690.71	33,443,555.30	8,360,888.83
D	118,039,423.34	23,727,607.21	138,258,473.65	26,801,073.57
L	195,214,905.99	48,754,718.52	223,998,051.44	55,532,380.08
-	62,720,373.89	9,408,056.08	61,917,014.54	9,287,552.18
	447,769,784.98	98,423,833.39	487,737,857.68	106,101,494.47

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.17 Deferred tax assets and deferred tax liabilities *(Continued)*

4.17.2 D

Item	Balance as at the end of the period		B	
	Taxable temporary differences	Deferred tax liabilities		D
A				
	148,639,144.46	37,159,786.12	165,697,546.44	41,424,386.62
C				
	39,633.60	5,945.04	13,879,270.75	2,081,890.61
O				
			47,809.41	7,171.41
	155,555,730.37	38,835,397.34	192,354,108.28	48,061,288.32
	304,234,508.43	76,001,128.50	371,978,734.88	91,574,736.96

4.17.3 D

Item	As at the end of the period		A	B
	Amount offset in deferred tax assets and liabilities	Balance of deferred tax assets or liabilities after the offset	A	
D	45,825,912.31	52,597,921.08	50,754,678.64	55,346,815.83
D	45,825,912.31	30,175,216.19	50,754,678.64	40,820,058.32

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.17 Deferred tax assets and deferred tax liabilities *(Continued)*

4.17.4 D

Item	Balance as at the end of the period	B
D	30,672,130.87	10,523,912.94
D	71,520,644.36	59,473,871.02
	102,192,775.23	69,997,783.96

4.17.5 D

Years	Balance as at the end of the period	B	Remark
2025		9,062,477.57	
2026	13,349,694.04	5,381,372.94	
2027	11,593,378.19	6,665,188.33	
2028	10,210,158.20	2,344,298.98	
2029	21,072,453.53	20,592,483.91	
2030	15,294,960.40	15,428,049.29	
	71,520,644.36	59,473,871.02	

4.18 Other non-current assets

Item	Balance as at the end of the period			B	
	Book balance	Provision for impairment	Book value	B	B
P	6,001,332.45		6,001,332.45	6,061,296.16	6,061,296.16
P	12,748,833.24		12,748,833.24	9,453,564.81	9,453,564.81
	18,750,165.69		18,750,165.69	15,514,860.97	15,514,860.97

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.19 Assets with restrictions on the ownership or use right

	As at the end of the period				A			
Item	Book balance	Book value	Type of restriction	Situation of restriction	B	B		
C	1,365,454.52	1,365,454.52	Frozen	Foreign exchange regulatory account	1,365,109.43	1,365,109.43	F	F
	11,000.00	11,000.00	ETC deposit	ETC deposit	5,000,000.00	5,000,000.00	F	P
L	254,502,240.91	254,502,240.91	Pledge	Pledged borrowings	254,502,240.91	254,502,240.91	P	P
F	92,963,976.96	28,770,653.11	Mortgage	Sale and leaseback	90,666,399.96	27,683,567.89	M	
	260,090,969.45	241,154,180.53	Mortgage	Mortgaged borrowings	260,090,969.45	248,248,404.63	M	M
I	102,114,565.11	89,344,625.89	Mortgage	Mortgaged borrowings	91,916,306.11	81,298,845.57	M	M
	711,048,206.95	615,148,154.96			703,541,025.86	618,098,168.43		

4.20 Short-term borrowings

Item	Balance as at the end of the period	B
M	121,000,000.00	93,720,000.00
G	23,675,386.56	15,523,676.71
	144,675,386.56	109,243,676.71

Notes to the Financial Statements

F M E 30 J 2026
(A MB)

4 N (C)

4.21 Financial liabilities held for trading

Item	Balance as at the end of the period	B
F		1,805,503.25
I :		1,805,503.25
		1,805,503.25

4.22 Notes payable

Category	Balance as at the end of the period	B
B	26,025,756.94	
	26,025,756.94	

4.23 Accounts payable

A :

Item	Balance as at the end of the period	B
1	117,073,811.68	156,277,714.53
1 2	6,061,477.26	2,848,066.71
2 3	269,266.74	1,229,010.41
O 3	567,171.30	448,300.83
	123,971,726.98	160,803,092.48

A 30 J 2026, 1 (31 D 2025:).

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.26 Employee benefits payable

4.26.1 P

Item	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
-	80,933,318.18	322,397,009.87	338,576,455.62	64,753,872.43
P -				
	3,498,174.72	23,270,242.79	23,170,130.44	3,598,287.07
	84,431,492.90	345,667,252.66	361,746,586.06	68,352,159.50

4.26.2 P -

Item	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
(1) , ,	78,429,558.56	288,208,788.87	304,534,202.79	62,104,144.64
(2) E	458,834.54	9,258,967.96	9,254,712.75	463,089.75
(3)	1,812,873.60	12,566,644.73	12,424,631.10	1,954,887.23
I :	1,724,186.71	11,826,955.00	11,699,201.81	1,851,939.90
	88,686.89	713,448.51	699,188.07	102,947.33
M		26,241.22	26,241.22	
(4) H	205,038.44	12,274,717.03	12,274,451.03	205,304.44
(5) L	27,013.04	87,891.28	88,457.95	26,446.37
	80,933,318.18	322,397,009.87	338,576,455.62	64,753,872.43

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.26 Employee benefits payable *(Continued)*

4.26.3 P

Item	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
B				
	3,399,051.09	22,571,585.05	22,478,282.79	3,492,353.35
	99,123.63	698,657.74	691,847.65	105,933.72
	3,498,174.72	23,270,242.79	23,170,130.44	3,598,287.07

A C G

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.28 Other payables

Item	Balance as at the end of the period	B
I		
D	3,116,253.00	3,600,000.00
O	80,519,342.54	88,259,119.30
	83,635,595.54	91,859,119.30

4.28.1 D

Item	Balance as at the end of the period	B
D		
	3,116,253.00	3,600,000.00
	3,116,253.00	3,600,000.00

Notes to the Financial Statements

F M E 30 2026
(A MB)

4 N (C)

4.28 Other payables *(Continued)*

4.28.2 O

Item	Balance as at the end of the period	B
P -	20,526,726.65	30,510,944.19
E	1,313,457.77	1,313,457.77
A	4,395,331.10	2,228,893.61
D	1,067,318.76	1,571,150.50
I	22,627,318.20	19,906,013.30
I	8,469,840.22	9,229,765.68
P	22,119,349.84	23,467,735.12
O		31,159.13
	80,519,342.54	88,259,119.30

4.29 Non-current liabilities due within one year

Item	Balance as at the end of the period	B
L -	203,240,000.00	132,990,000.00
L -	11,107,283.00	31,995,109.32
L	40,528,777.46	36,422,400.23
	254,876,060.46	201,407,509.55

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.30 Other current liabilities

Item	Balance as at the end of the period	B
O	16,132.08	2,785,649.87
A	1,802,126.86	429,217.10
	1,818,258.94	3,214,866.97

4.31 Long-term borrowings

Item	Balance as at the end of the period	B
P	14,500,000.00	59,000,000.00
M	530,441,355.05	556,222,957.47
G	251,090,000.00	264,720,000.00
L : -	203,240,000.00	132,990,000.00
	592,791,355.05	746,952,957.47

4.32 Lease liabilities

Item	Balance as at the end of the period	B
L	175,114,905.95	184,898,051.41
I :	-34,850,419.80	-15,215,483.11
L :	40,528,777.46	36,422,400.23
	134,586,128.49	148,475,651.18

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.33 Long-term payables

Item	Balance as at the end of the period	B
L -	62,658,100.16	47,419,832.76
	62,658,100.16	47,419,832.76

4.33.1 L -

Item	Balance as at the end of the period	B
A	73,765,383.16	79,414,942.08
I :	-11,833,240.92	-9,413,872.18
L : - 1	11,107,283.00	31,995,109.32
	62,658,100.16	47,419,832.76

4.34 Deferred income

Item	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period	F
A	18,206,515.00		151,896.00	18,054,619.00	A
	18,206,515.00		151,896.00	18,054,619.00	/

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.35 Share capital

Item	B	Changes in the current period ("+" for increase and "-" for decrease)					Balance as at the end of the period
		New shares issued	Bonus shares	Capital reserve to shares	Others	Subtotal	
	72,358,900.00						72,358,900.00

4.36 Capital reserves

Item	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period

Notes to the Financial Statements

F M E 30 2026

(A MB)

4 N (C)

4.37 Treasury stock

Item	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
C	28,666,701.91			28,666,701.91
C	19,148,923.26			19,148,923.26
	47,815,625.17			47,815,625.17

4.38 Surplus reserves

Item	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
	38,399,577.13			38,399,577.13
	38,399,577.13			38,399,577.13

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.39 Retained earnings

Item	Amount for the current period	A
	364,230,299.84	344,285,828.01
(+ -)		
	364,230,299.84	344,285,828.01
P :	33,773,135.56	54,395,979.83
L :		
C	16,883,200.00	34,451,508.00
C	381,120,235.40	364,230,299.84

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.40 Revenue and cost of sales

4.40.1 D

Item	Amount for the current period		A	
	Income	Cost	I	C
P	709,707,141.17	532,214,182.32	690,902,820.42	523,893,300.01
O	119,774,272.93	92,860,195.07	47,658,804.91	25,440,894.13
	829,481,414.10	625,074,377.39	738,561,625.33	549,334,194.14

B :

Item	Amount for the current period	A
I	709,707,141.17	690,902,820.42
	709,707,141.17	690,902,820.42
I	119,774,272.93	47,658,804.91
	72,542,654.92	28,287,517.76
M		1,485,148.52
	364,085.42	906,058.96
O	46,867,532.59	16,980,079.67
	829,481,414.10	738,561,625.33

4.40.2 N

Item	Time for fulfillment of performance obligations	Significant payment terms	Nature of the Company's transfer of the promised goods	Whether the Company is acting as principal	Amounts assumed by the Company that are expected to be refunded to customer	Types of quality assurance provided by the Company and relevant obligations
	A	B	D ,		N	N

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.41 Taxes and surcharges

Item	Amount for the current period	A
H	4,044,129.97	3,786,940.26
	453,852.11	400,163.50
E	328,417.32	291,972.68
L	1,079,034.49	423,158.41
	235,617.93	203,170.66
O	11,138.34	11,652.83
	6,152,190.16	5,117,058.34

4.42 Selling and distribution expenses

Item	Amount for the current period	A
E	1,702,541.53	1,717,804.62
D	21,628.54	21,434.73
A		71.70
A	9,191.07	29,673.69
B	47,302.87	127,110.28
O	87,248.50	34,948.45
	82,855.20	57,237.67
O	58,494.59	27,282.10
B	1,543,772.77	1,548,324.27
M	124,588.41	13,220.19
O	26,499.09	111,172.30
	3,704,122.57	3,688,280.00

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.43 General and administrative expenses

Item	Amount for the current period	A
E	69,008,634.48	68,866,158.00
D	10,356,445.04	9,568,562.60
A	1,789,200.55	1,240,295.67
A	4,344,233.31	4,578,911.00
D	1,277,649.31	1,015,879.66
H	2,843,090.16	2,543,931.61
E	801,038.28	2,828,664.55
O	2,043,230.53	2,076,294.46
	1,719,011.10	2,038,653.17
	687,070.60	468,156.24
P	2,599,524.24	5,767,986.12
D	13,249.47	491.00
O	1,897,472.97	1,842,098.47
C	4,884,530.33	2,109,563.44
A	2,966,000.00	2,556,000.00
M	4,445,881.39	4,727,974.11
B	1,792,197.76	2,438,681.43
O	3,940,680.17	7,151,356.84
	117,409,139.69	121,819,658.37

4.44 Research and development expenditures

Item	Amount for the current period	A
E	15,089,008.80	15,238,152.21
D	88,989.98	160,973.20
D	181,995.54	
	13,491.28	2,257.42
O	84,590.00	95,219.00
	35,969.73	
O	116,733.33	166,320.89
	15,610,778.66	15,662,922.72

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.45 Financial expenses

Item	Amount for the current period	A
I	17,354,423.12	18,377,254.10
I :	4,258,335.69	4,653,633.38
L :	1,876,835.76	587,377.24
G	73,292.86	2,486.65
O	2,578,894.69	4,214,451.98
	18,129,774.91	22,006,815.49

4.46 Other income

Item	Amount for the current period	A
G	6,020,713.48	10,568,938.30
A		792,415.54
	245,276.05	240,461.59
O	663,644.85	
	6,929,634.38	11,601,815.43

4.47 Investment income

Item	Amount for the current period	A
I -	3,177,287.11	-1,206,158.07
I -	5,864,305.45	5,032,728.01
I		5,699.09
I	-1,994,496.75	
	7,047,095.81	3,832,269.03

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.48 Profit from changes in fair value

Sources of the gains from changes in fair value	Amount for the current period	A
F	342,935.53	428,261.38
O -	39,633.60	49,582.16
	382,569.13	477,843.54

4.49 Losses from credit impairment

Item	Amount for the current period	A
L	18,546,741.82	161,794.74
L	-638,417.46	-7,778,677.18
	17,908,324.36	-7,616,882.44

4.50 Income from asset disposal

Item	Amount for the current period	A	A -
G -			
(-)	46,657.62	1,250,151.08	46,657.62
I : G			
(-)	12,785.02	1,250,151.08	12,785.02
G -			
(-)	33,872.60		33,872.60
	46,657.62	1,250,151.08	46,657.62

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.51 Non-revenue

Item	Amount for the current period	A	A
G			
-	215,040.11	1,710.88	215,040.11
I :	215,040.11	1,710.88	215,040.11
A	0.58		0.58
G C	245.00	4,289.60	245.00
O	1,575,121.72	60,456.37	1,575,121.72
	1,790,407.41	66,456.85	1,790,407.41

4.52 Non-operating expenses

Item	Amount for the current period	A	A
L			
-	264,215.51	794,076.29	264,215.51
I :	264,215.51	790,326.29	264,215.51
		3,750.00	
E	49,193.44	734,227.10	49,193.44
E	1,127,708.31	548,818.70	1,127,708.31
A	15,829,539.54	1,446,966.18	15,829,539.54
O	703,591.44	274,456.19	703,591.44
	17,974,248.24	3,798,544.46	17,974,248.24

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.53 Income tax expenses

4.53.1

Item	Amount for the current period	A
C	9,423,579.22	13,016,683.24
D	-7,895,947.38	2,193,768.79
	1,527,631.84	15,210,452.03

4.53.2 A

Item	Amount for the current period
	23,714,822.47
I	3,557,223.37
I	-445,127.90
I	-1,924,407.16
I	-143,621.66
E	2,589,317.55
I	-6,974,166.39
E	
	8,722,546.29
I &D	-2,439,915.09
I	-1,414,217.17
I	1,527,631.84

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.54 Earnings per share

4.54.1 B

B C :

Item	Amount for the current period	A
C	33,773,135.56	36,530,359.57
C	70,399,100.00	72,618,150.00
B	0.48	0.50
I :	0.48	0.50
B		

4.54.2 D

D C ( ) C ( ):

Item	Amount for the current period	A
C ( )	33,773,135.56	36,530,359.57
C ( )	70,399,100.00	72,618,150.00
D	0.48	0.50
I :	0.48	0.50
D		

Notes to the Financial Statements

F M E 30 2026

(A MB)

4 N (C)

4.55 Supplementary information to the statement of cash flows

4.55.1

Supplementary information	Amount for the current period	A
1. N		
N	22,187,190.63	26,769,118.15
A :	17,908,324.36	-7,616,882.44
L		
D	33,204,272.29	27,291,312.70
D		
D -	16,339,755.30	17,436,605.58
A	14,543,432.78	10,883,372.70
A -	19,734,762.66	19,130,569.27
L		
- (-)	-46,657.62	-1,250,151.08
L -		
(-)	49,175.40	792,365.41
L		
(-)	-382,569.13	-477,843.54
F (-)	17,431,178.54	18,379,740.75
I (-)	-7,047,095.81	-3,832,269.03
D		
(-)	2,748,894.75	3,763,953.21
I		
(-)	-10,644,842.13	-3,865,899.31
D (-)	2,268,807.01	991,468.82
D		
(-)	10,118,117.77	254,827,632.87
I		
(-)	-28,351,637.78	-167,522,553.50
O	1,487,600.60	2,821,077.50
N	111,548,709.62	198,521,618.06

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.55 Supplementary information to the statement of cash flows *(Continued)*

4.55.1 (C)

Supplementary information	Amount for the current period	A
2. :		
C		
C		
-		
3. N :		
E	310,912,508.17	333,106,635.79
L :	287,672,625.54	255,232,744.16
P :		
L :		
N	23,239,882.63	77,873,891.63

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

4 N (C)

4.55 Supplementary information to the statement of cash flows *(Continued)*

4.55.2 B

Item	Balance as at the end of the period	B
I. C	310,912,508.17	333,106,635.79
I :	239,908.03	195,546.26
	309,704,141.67	332,122,993.91
O	968,458.47	788,095.62
II. C		
I :		
III. B	310,912,508.17	333,106,635.79

4.56 Foreign currency monetary items

4.56.1 F

Item	Balance of foreign currency as at the end of the period	C	B MB
C			279,489.95
I : D	40,010.68	6.8109	272,508.74
HKD	8,037.77	0.86855	6,981.21

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

5 C

5.1 Changes in scope of consolidation for other reasons

1. O 14 J 2026, G D C C ., L . MB1 ,

2. O 5 F 2026, G D O N C ., L . MB1 ,

3. O 13 M 2026, G D E C ., L . MB0.5 ,

4. O 21 M 2026, G K H M C ., L .

Notes to the Financial Statements

F M E 30 2026

(A MB)

6 E

6.1 Equities in subsidiaries

6.1.1

Name of subsidiary	Category of legal person	Registered capital (ten thousand)	Main place of business	Registration place	Nature of business	Shareholding ratio (%) Direct	Shareholding ratio (%) Indirect
E H C L	L	33,000.00			H	100.00	
C N C C L	L	1,000.00	C	C	M		100.00
O E H C L	L	1,000.00			M		65.00
C H C L	L	2,585.98			M		100.00
P C H C L	L	3,057.47			M		100.00
I M H C L	L	9,800.00			M		100.00
N H C L	L	500.00			M		100.00
H H C L	L	5,000.00	H	H	M		65.00
D C C L	L	200.00			E		100.00
D N C L	L	100.00			E		100.00

Notes to the Financial Statements

F M E 30 2026

(A MB)

6 E (C)

6.1 Equities in subsidiaries *(Continued)*

6.1.1 (C)

Name of subsidiary	Category of legal person	Registered capital (ten thousand)	Main place of business	Registration place	Nature of business	Shareholding ratio (%) Direct	Indirect
P C., L.	L	1,000.00	L	L	P		100.00
D C., L.	L	100.00			E		100.00
D C C., L.	L	100.00			E		100.00
D E C., L.	L	50.00			P		100.00
K H M (G) C., L.	L	20,000.00	N	N	H	100.00	
P K H C., L.	L	600.00	P	P	M		100.00
G H C., L.	L	6,000.00			M		100.00
H C., L.	L	3,000.00			M		60.00
L C H C., L.	L	1,000.00			M		51.00
K H C., L.	L	1,000.00			M		51.00
H C H C., L.	L	100.00	H	H	M		100.00
CMC C., L.	L	500.00			M		100.00

Notes to the Financial Statements

F M E 30 2026

(A MB)

6 E (C)

6.1 Equities in subsidiaries *(Continued)*

6.1.1 (C)

Name of subsidiary	Category of legal person	Registered capital (ten thousand)	Main place of business	Registration place	Nature of business	Shareholding ratio (%) Direct	Shareholding ratio (%) Indirect
J H C., L.	L	1,000.00	H	H			100.00
N H C., L.	L	1,000.00	N	N	M		85.65
H P H C., L.	L	3,000.00	H	H	M		51.00
H C., L.	L	1,000.00			M		90.00
N P H C., L.	L	753.00			M		68.80
B H C., L.	L	4,653.67	B	B	M		67.77
H C., L.	L	50.00					100.00
K H C., L.	L	1,000.00			M		95.00
H C., L.	L	2,040.82	H	H			98.00
P C., L.	L	50.00			P		100.00
P I H ( )C., L.	L	500.00			H		100.00

Notes to the Financial Statements

F M E 30 2026

(A MB)

6 E (C)

6.1 Equities in subsidiaries *(Continued)*

6.1.1 (C)

Name of subsidiary	Category of legal person	Registered capital (ten thousand)	Main place of business	Registration place	Nature of business	Shareholding ratio (%) Direct	Indirect
D P C., L.	L	1,000.00			P		80.00
C K P H C., L.	L	1,000.00	C	C	M		64.55
H C., L.	L	100.00	H	H	N		100.00
L C H C., L.	L	5,000.00			M		100.00
H	L	6,000.00			M		55.00
H H C., L.	L	1,400.00	J	J	M		95.00
K H H C., L.	L	1,000.00	H	H	M		80.00
L K H C., L.	L	3,000.00	L	L	M		100.00
J P H C., L.	L	2,083.33	C	C	M		49.33
G F H C., L.	L	1,000.00			M		100.00
C K H C., L.	L	5,000.00	C	C	M	100.00	
K H C., L.	L	500.00			M	100.00	
L K H C., L.	L	200.00			M	85.00	
Q K H C., L.	L	436.00	L	L	M	100.00	
K F C	F I A	50.00			F	100.00	

Notes to the Financial Statements

F M E 30 2026

(A MB)

6 E (C)

6.1 Equities in subsidiaries *(Continued)*

6.1.1 (C)

Name of subsidiary	Category of legal person	Registered capital (ten thousand)	Main place of business	Registration place	Nature of business	Shareholding ratio (%) Direct	Shareholding ratio (%) Indirect
H C., L.	L	10,000.00			M	60.00	
K H C., L.	L	2,700.00			M	100.00	
H C., L.	L	2,398.26	J	J	M	55.00	
C K K H C., L.	L	2,040.00	L	L	M	51.00	
H C., L.	L	1,800.00			M	51.00	
K P C C., L.	L	50.00			M	100.00	
J K C E I P (L P)	L P	6,001.00	J	J	E I	66.60	33.30
K P M C., L.	L L C	2,764.00	L	L	P	100.00	

Notes to the Financial Statements

F M E 30 J 2026
(A MB)

6 E (C)

6.1 Equities in subsidiaries *(Continued)*

6.1.1 (C)

N :

A A A O E H C ., L ., , - , 100%.

B :

C H P C ., L . 90% G H C ., L . A 30 J 2026, H P C ., L . , , , 90% G H C ., L . C .

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

6 E (C)

6.1 Equities in subsidiaries *(Continued)*

6.1.2 - - ,

Name of subsidiaries	Shareholding ratio of minority shareholders (%)	Profit or loss attributable to minority shareholders in current period	Dividends declared to be distributed to minority shareholders in current period	Balance of minority equity as at the end of the period
L H C ., L .	40.00%	-381,085.32		37,184,554.51
J H C ., L .	45.00%	-596,143.69		12,682,248.23
D P C ., L .	20.00%	47,364.17		21,151,410.14
H C ., L .	35.00%	-501,395.59		6,121,811.68

Notes to the Financial Statements

F M E 30 2026

(A MB)

6 E (C)

6.1 Equities in subsidiaries *(Continued)*

6.1.3 M - -

Name of subsidiary	Balance as at the end of the period					
	Current assets	Non-current assets	Total assets	Current liabilities	Non-current liabilities	Total liabilities
H C ., L .	8,275,928.65	256,048,929.84	264,324,858.49	63,396,592.19	107,966,880.00	171,363,472.19
J H C ., L .	14,026,449.93	64,850,234.65	78,876,684.58	12,118,270.67	37,268,812.28	49,387,082.95
D P C ., L .	145,561,539.07	667,118.17	146,228,657.24	69,285,043.34		69,285,043.34
H H C ., L .	12,918,639.00	64,377,251.59	77,295,890.59	13,693,726.58	46,111,273.51	59,805,000.09

N	B					
		N -			N -	
H C ., L .	17,496,897.22	252,013,016.41	269,509,913.63	63,628,434.03	111,967,380.00	175,595,814.03
J H C ., L .	11,524,763.22	66,782,837.21	78,307,600.43	10,076,431.15	37,468,468.46	47,544,899.61
D P C ., L .	172,867,810.34	853,963.27	173,721,773.61	112,153,608.69		112,153,608.69
H H C ., L .	13,183,362.26	72,877,579.64	86,060,941.90	16,371,612.88	50,765,879.69	67,137,492.57

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

6 E (C)

6.1 Equities in subsidiaries *(Continued)*

6.1.3 M - - (C)

	Amount for the current period				A			C
Name of subsidiary	Revenue	Net profit	Total comprehensive income	Cash flows from operating activities		N		
H C., L.	5,016,055.05	-952,713.30	-952,713.30	17,693,020.15	13,761.47	-683,346.83	-683,346.83	14,612,783.16
J H C., L.	12,949,747.38	-1,324,763.75	-1,324,763.75	-292,282.48	9,909,096.61	-4,111,185.55	-4,111,185.55	-3,327,701.92
D P C., L.	128,466,718.11	15,375,448.98	15,375,448.98	-31,935,631.23	102,090,901.20	28,837,924.34	28,837,924.34	27,158,954.04
H H C., L.	16,101,468.12	-1,432,558.83	-1,432,558.83	608,107.82	2,637,455.19	-75,355.35	-75,355.35	1,151,765.67

6.2 Equity in joint venture arrangements or associates

6.2.1

Name of joint ventures or associates	Main place of business	Registration place	Nature of business	Shareholding ratio (%)		Accounting treatment method for investments in joint ventures or associates	Whether it is strategic for the Company's activities
				Direct	Indirect		
H A M C., L.	H	H	H	30.81		E	
H L C., L.			M	45.00		E	

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

6 E (C)

6.2 Equity in joint venture arrangements or associates *(Continued)*

6.2.2 M

	Balance as at the end of the period/Amount for the current period		B /A	
	Anken Medical	Longwan Yining	A M	L
O	73,237,217.14	1,235,241.16	85,678,453.82	1,862,472.90
N -	34,142,438.95	268,304,608.47	48,717,351.43	255,093,748.77
	107,379,656.09	269,539,849.63	134,395,805.25	256,956,221.67
O	103,494,330.10	42,548,204.79	114,712,460.18	41,510,269.10
N -	14,748,126.71	103,231,201.99	10,470,922.46	90,995,141.93
	118,242,456.81	145,779,406.78	125,183,382.64	132,505,411.03
M	-53,860.73		994,578.73	
E	10,916,661.45	123,760,442.85	8,217,843.88	124,450,810.64
N				
A	6,784,746.95		6,784,746.95	
G	6,784,746.95		6,784,746.95	
O				
B	10,148,089.38	55,692,199.28	9,316,664.65	56,002,864.79
F				
N	2,698,817.57	-690,367.79	7,944,500.27	-937,586.27
N				
O	2,698,817.57	-690,367.79	7,944,500.27	-937,586.27
D				

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

7 G

7.1 Government grants included in the current profit or loss

Type	Amount for the current period	A
A	151,896.00	151,896.00
I	5,868,817.48	10,417,042.30
	6,020,713.48	10,568,938.30

7.2 Liability items involving government grants

Liability items	B	Newly increased subsidy amount in the current period	Amount included in non-operating revenue in the current period	Amount transferred to other income in the current period	Costs and expenses written off in the current period	Other changes	Balance as at the end of the period	Related to assets/related to income
D	18,206,515.00			151,896.00			18,054,619.00	Related to assets

Notes to the Financial Statements

F M E 30 2026

(A MB)

8

8.1 Various risks generated by financial instruments

C ( ), ( ).

C :

B D C ' C ' C . C C . C ' C . M C B D . M C , C . C ' A C .

C ,

Notes to the Financial Statements

F M E 30 2026

(A MB)

8 (C)

8.1 Various risks generated by financial instruments *(Continued)*

8.1.1 C

C C

C

C

C

C

3091 2 (60.5 ( )0.5 (50.6 ( )0.5 ( )0. ( )0.5 ( )0.5 (

Notes to the Financial Statements

F M E 30 2026

(A MB)

8 (C)

8.1 Various risks generated by financial instruments *(Continued)*

8.1.2 L

L C . L C . 12 C . A ,
C ,

Notes to the Financial Statements

F M E 30 2026

(A MB)

8 (C)

8.1 Various risks generated by financial instruments *(Continued)*

8.1.2 L (C)

C :

Item	Balance as at the end of the period						
	Instant repayment	Within 1 year	1 – 2 years	2 – 5 years	Over 5 years	Total undiscounted contractual amount	Book value
B		347,915,386.56	206,799,626.30	261,353,295.70	235,587,941.03	1,051,656,249.59	940,706,741.61
L		40,528,777.46	39,243,645.50	75,099,994.10	55,092,908.69	209,965,325.75	175,114,905.95
L -		11,107,283.00	18,837,193.31	55,654,147.77		85,598,624.08	73,765,383.16
A		117,073,811.68	6,061,477.26	836,438.04		123,971,726.98	123,971,726.98
O		64,876,249.27	169,826.27	18,589,520.00		83,635,595.54	83,635,595.54
		581,501,507.97	271,111,768.64	411,533,395.61	290,680,849.72	1,554,827,521.94	1,397,194,353.24

I	B					
	I					
	1	1 2	2 5	O 5		B
B	242,233,676.71	206,799,626.30	261,353,295.70	389,749,543.45	1,100,136,142.16	989,186,634.18
L	36,422,400.23	26,754,091.69	87,529,357.31	48,765,941.63	199,471,790.86	184,898,051.41
L -	31,995,109.32	29,568,765.29	25,332,759.87		86,896,634.48	79,414,942.08
A	156,277,714.53	2,848,066.71	1,229,010.41		160,354,791.65	160,354,791.65
O	3,927,949.30	49,230,863.16	38,700,306.84		91,859,119.30	91,859,119.30
	470,856,850.09	315,201,413.15	414,144,730.13	438,515,485.08	1,638,718,478.45	1,505,713,538.62

Notes to the Financial Statements

F M E 30 2026

(A MB)

8 (C)

8.1 Various risks generated by financial instruments *(Continued)*

8.1.3 M

M

(1) I

I

F C

C

(2) E

E

C

C

Notes to the Financial Statements

F M E 30 2026

(A MB)

8 (C)

8.1 Various risks generated by financial instruments *(Continued)*

8.1.3 M (C)

(2) E (C)

C D, MB :

	Balance as at the end of the period			B	O	
Item	USD	Other foreign currency	Total	D		
M	272,508.74	6,981.21	279,489.95	276,692.10	49,750.10	326,442.20

Notes to the Financial Statements

F M E 30 2026

(A MB)

9 D

: L 1 L 2 L 1 L 3 .

9.1 Fair value of assets and liabilities measured at fair value as at the end of the period

Item	Fair value as at the end of the period			
	Measured at fair value at Level 1	Measured at fair value at Level 2	Measured at fair value at Level 3	Total
I. Continuous measurement of fair value				
◆ F			8,916,323.73	8,916,323.73
1. F				
			8,916,323.73	8,916,323.73
(1) I				
			8,916,323.73	8,916,323.73
◆ O -				
			23,922,657.55	23,922,657.55
1. F				
			23,922,657.55	23,922,657.55
(1) I				
			23,922,657.55	23,922,657.55
Total assets with continuous measurement at fair value			32,838,981.28	32,838,981.28

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

9 D (C)

9.2 Qualitative and quantitative information on the valuation techniques and important parameters adopted for continuous and non-continuous measurements of fair values at level 3

Item	Fair value as at the end of the period	Valuation techniques	Unobservable inputs	Range (Weighted average)
F	8,916,323.73 (23.722)	0.55	0.556	( ) (3.8)

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

10 (C)

10.3 Joint ventures and associates of the Company

P N 6 E C .

O C :

Name of joint venture or associate	Relationship with the Company	
H A M C ., L .	A	C
L H C ., L .	A	C
H M C C ., L .	A	C
C H K H C ., L .	A	C
F N C ., L .	A	C
O H M C ., L .	A	C

Notes to the Financial Statements

F M E 30 2026

(A MB)

10 (C)

10.5 Information on related party transactions *(Continued)*

10.5.2 -

C :

The guaranteed	Guarantee amount	Starting date of guarantee	Maturity date of guarantee	Whether the guarantee has been performed
Q H C ., L .	60,000,000.00	2023/10/9	2034/10/9	N
K H C ., L .	60,000,000.00	2019/8/20	2031/8/21	N
L C H C ., L .	68,440,000.00	2023/4/3	2032/3/2	N
H A M C ., L .	32,400,000.00	2024/7/1	2027/6/30	N
H C ., L .	8,400,000.00	2024/3/31	2027/3/31	N
H C ., L .	103,000,000.00	2023/10/12	2034/10/9	N
K H C ., L .	12,000,000.00	2024/7/18	2029/6/18	N
M H C ., L .	8,000,000.00	2024/7/18	2029/6/18	N
Q K H C ., L .	5,300,780.00	2024/1/1	2028/12/31	N
G H C ., L .	4,337,088.00	2024/1/25	2028/12/25	N
P C H C ., L .	26,000,000.00	2023/12/20	2031/12/20	N

Notes to the Financial Statements

F M E 30 2026

(A MB)

10 (C)

10.5 Information on related party transactions *(Continued)*

10.5.2 (C)

C :

Guarantor	Guarantee amount	Starting date of guarantee	Maturity date of guarantee	Whether the guarantee has been fulfilled
K H C ., L .	200,000,000.00	2021/12/24	2026/12/24	N
K H C ., L .	200,000,000.00	2021/12/24	2026/12/24	N
C K H C ., L .	200,000,000.00	2021/12/24	2026/12/24	N
G H C ., L .	200,000,000.00	2021/12/24	2026/12/24	N
P K H C ., L .	200,000,000.00	2021/12/24	2026/12/24	N
H C ., L .	200,000,000.00	2021/12/24	2026/12/24	N
C H C ., L .	200,000,000.00	2021/12/24	2026/12/24	N
C K H C ., L .	66,474,000.00	2021/12/24	2026/12/10	N
, L	24,000,000.00	2020/6/30	2027/6/30	N
, H , L	79,642,127.25	2021/11/29	2028/11/29	N
, H , L	180,950,000.00	2020/10/26	2026/10/25	N
	70,000,000.00	2023/11/8	2026/11/15	N
, L , H	14,660,000.00	2019/9/10	2029/8/20	N
, L , H	10,280,000.00	2020/1/1	2029/8/20	N
, L , H	3,320,000.00	2020/12/22	2029/8/20	N
, L , H	2,200,000.00	2020/9/27	2029/8/20	N
, L , H	2,200,000.00	2020/9/27	2029/8/20	N
, L , H	3,050,000.00	2021/3/1	2029/8/20	N
, L , H	3,050,000.00	2021/3/1	2029/8/20	N
, L , H	45,000,000.00	2023/7/3	2037/12/31	N
, L , H	15,000,000.00	2023/7/31	2037/12/31	N
, L , H	10,116,550.00	2023/10/25	2037/12/31	N
, L , H	5,007,200.00	2023/11/24	2037/12/31	N
, E				
C C ., L .,				
P M C ., L .	60,000,000.00	2023/10/9	2031/10/9	N
L	18,312,000.00	2023/12/20	2028/12/25	N
, L	25,000,000.00	2024/12/10	2027/12/10	N
, L	120,000,000.00	2024/3/27	2027/3/26	N

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

10 (C)

10.5 Information on related party transactions *(Continued)*

10.5.3 L

Related parties	Lending/ borrowing amount	Commencement date	Expiry date	Remark
Loans from related parties				
P M C ., L .	2,508,250.00	2022/6/13		N
Loan to related parties				
L H C ., L .	14,050,000.00	2023/1/10		
H P C ., L .	10,204,311.69	2015/6/1		
C	3,490,447.08	2015/9/1		

10.5.4

Item	Amount for the current period	A
, .	3,859,928.05	3,911,019.68

6

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

10 (C)

10.6 Unsettled items of receivables from and payables to related parties *(Continued)*

10.6.2 P

Item	Related parties	Book balance as at the end of the period	B
A			
	F N C ., L .	81,526.00	21,376.00
	L	83,361.08	34,697.95
O			
	D P M C ., L .	20,000,000.00	18,000,000.00
	L H C ., L .		1,095,000.00
	P M C ., L .	2,508,250.00	2,508,250.00
		900,000.00	
	L	2,726,130.87	2,726,130.87
		900,000.00	900,000.00

Notes to the Financial Statements

F M E 30 2026
(A MB)

10 (C)

10.7 Top five highest remunerated individuals

F J 2026, C 2
D (J 2025: 3 D), 3
:

Item	Amount for the current period	A
B , ,		
	1,142,065.87	905,073.38
-	164,835.38	107,525.76
	1,306,901.25	1,012,599.14

Remuneration range	Persons in the current period	P
0-500,000.00	3	1
500,000.00-1,000,000.00		1
	3	2

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

11 -

I H A 2023 C 27, 2023, C H A C ' , C ' H - C ' C ' H A 5% C ' .556 2 9 9 53

Notes to the Financial Statements

F M E 30 J 2026
(A MB)

11 - (C)

A H A H
:

Vesting period	Vesting schedule	Vesting ratio
F	F 12	25%
	F 12 24	25%
	F 24 36	25%
F	F 36 48	25%

11.1 Equity-settled share-based payment

Determination method of the fair value of equity instruments on the date of grant	Market method
I C	
B	
A - -	54,846,169.88

Notes to the Financial Statements

F M E 30 2026

(A MB)

11 (C)

11.2 Share-based payment fee

	Amount for the current period			A	
Granting object	Equity-settled share-based payments	Cash-settled share-based payments	Total	E - C -	
H A	1,487,600.60		1,487,600.60	2,831,843.05	2,831,843.05
	1,487,600.60		1,487,600.60	2,831,843.05	2,831,843.05

12 C

12.1 Significant commitments

12.1.1 C

C :

Item	June 30, 2026	D 31, 2025
H	37,807,218.01	25,533,926.00
	37,807,218.01	25,533,926.00

12.2 Contingencies

C

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

13 P

C

14 C

C :

E C

D

C

C

A :

	Balance as at the end of the period	B
D	54.85%	56.65%

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

15 O

15.1 Segment information

E C D C ,

A C G I J 2021,
C .

16 N

16.1 Accounts receivable

16.1.1 D

Aging	Balance as at the end of the period	B
1 (1)	39,995,300.56	42,090,776.46
1 2	4,202,467.36	4,493,170.46
2 3	4,368,885.88	2,644,852.66
	48,566,653.80	49,228,799.58
L :	12,787,660.36	12,544,534.74
	35,778,993.44	36,684,264.84

C ,

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

16 N *(C)*

16.1 Accounts receivable *(Continued)*

16.1.2 D

	Balance as at the end of the period					B				
	Book balance		Provision for bad debts			B		P		
Type	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value	A	P (%)	A	P (%)	B
P										
	9,311,538.89	19.17	9,311,538.89	100.00		11,916,666.11	24.21	11,916,666.11	100.00	
I :										
M	9,311,538.89	19.17	9,311,538.89	100.00		11,916,666.11	24.21	11,916,666.11	100.00	
P										
	39,255,114.91	80.83	3,476,121.47	8.86	35,778,993.44	37,312,133.47	75.79	627,868.63	1.68	36,684,264.84
I :										
P	39,255,114.91	80.83	3,476,121.47	8.86	35,778,993.44	37,312,133.47	75.79	627,868.63	1.68	36,684,264.84
	48,566,653.80	100.00	12,787,660.36	/	35,778,993.44	49,228,799.58	100.00	12,544,534.74	/	36,684,264.84

:

	Balance as at the end of the period				B	P
Name	Book balance	Provision for bad debts	Proportion of provision (%)	Basis of provision	B	
M	9,311,538.89	9,311,538.89	100.00	Provision for bad debts for lifetime expected credit losses	11,916,666.11	11,916,666.11
	9,311,538.89	9,311,538.89	/	/	11,916,666.11	11,916,666.11

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

16 N *(C)*

16.1 Accounts receivable *(Continued)*

16.1.2 D (C)

P :

I :

Name

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

16 N
(C)

16.2 Other receivables *(Continued)*

16.2.2 D

Item (or Investee)	Balance as at the end of the period	B
C K H C ., L .	12,400,000.00	12,400,000.00
K H C ., L .	5,500,000.00	7,000,000.00
Q K H C ., L .	5,300,000.00	5,300,000.00
K H C ., L .	10,000,000.00	16,000,000.00
Q K P M C ., L .	10,700,000.00	10,700,000.00
L K H C ., L .	17,000,000.00	17,000,000.00
	60,900,000.00	68,400,000.00
L :		
	60,900,000.00	68,400,000.00

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

16 N (C)

16.2 Other receivables *(Continued)*

16.2.3 O

(1) D

Aging	Balance as at the end of the period	B
1 (1)	150,858,666.43	129,893,005.85
1 2	129,891,946.17	189,701,628.70
2 3	82,390,076.46	109,787,806.90
3 4	48,104,769.57	52,311,522.50
4 5	6,674,442.01	496,167.22
M 5	700,979.96	702,979.96
	418,620,880.60	482,893,111.13
L :	1,270,466.81	1,217,310.23
	417,350,413.79	481,675,800.90

Notes to the Financial Statements

F M E 30 2026

(A MB)

16 N (C)

16.2 Other receivables *(Continued)*

16.2.3 O (C)

(2) D

	Balance as at the end of the period					B				
	Book balance		Provision for bad debts			B		P		
Category	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value	A	P (%)	A	P (%)	B
P										
	418,620,880.60	100.00	1,270,466.81	0.30	417,350,413.79	482,893,111.13	100.00	1,217,310.23	0.25	481,675,800.90
I :										
P										
	55,977,098.98	13.37	1,270,466.81	2.27	54,706,632.17	54,961,446.39	11.38	1,217,310.23	2.21	53,744,136.16
	362,643,781.62	86.63			362,643,781.62	427,931,664.74	88.62			427,931,664.74
	418,620,880.60	100.00	1,270,466.81	/	417,350,413.79	482,893,111.13	100.00	1,217,310.23	/	481,675,800.90

Notes to the Financial Statements

F M E 30 2026

(A MB)

16 N (C)

16.2 Other receivables *(Continued)*

16.2.3 O (C)

(2) D (C)

P :

I :

Name	Balance as at the end of the period		
	Other receivables	Provision for bad debts	Proportion of provision (%)
P	55,977,098.98	1,270,466.81	2.27
	362,643,781.62		
	418,620,880.60	1,270,466.81	/

Notes to the Financial Statements

F M E 30 2026

(A MB)

16 N (C)

16.2 Other receivables *(Continued)*

16.2.3 O (C)

(3) I

Provision for bad debts	Stage I Expected credit losses for the next 12 months	Stage II Lifetime expected credit loss (without credit impairment)	Stage III Lifetime expected credit loss (with credit impairment)	Total
B	1,217,310.23			1,217,310.23
I				
II				
III				
II				
I				
P	53,156.58			53,156.58
O				
B	1,270,466.81			1,270,466.81

(4) P

Category	B	Changes in the current period Provision	Recovery or reversal	Write-off or charge-off	Other changes	Balance as at the end of the period
P	1,217,310.23	53,156.58				1,270,466.81
	1,217,310.23	53,156.58				1,270,466.81

Notes to the Financial Statements

F M E 30 J 2026
(A MB)

16 N (C)

16.3 Long-term equity investments *(Continued)*

16.3.1 I

I	B ( )	B	Increase/decrease in current period: Additional investment	Reduced investment	Provision for impairment in current period	Others	Balance (book value) as at the end of the period	Balance of provision for impairment as at the end of the period
L K K H C ., L .	13,715,000.00			255,000.00			13,460,000.00	
K J F C K H M C ., L .	500,000.00						500,000.00	
C ., L .	204,916,953.81		101,327.06				205,018,280.87	
C K H C ., L .	52,790,529.72		10,310.22				52,800,839.94	
K H C ., L .	2,197,499.15		13,256.04				2,210,755.19	
K H C ., L .	27,787,023.18		20,620.44				27,807,643.62	
Q K H C ., L .	5,216,644.25						5,216,644.25	
L K H C ., L .	4,833,589.49		5,639.08				4,839,228.57	
L H C ., L .	60,000,000.00						60,000,000.00	
J H C ., L .	29,051,800.00		51,664.56				29,103,464.56	
D L H C ., L .	14,510,000.00						14,510,000.00	
K P C C ., L .	500,000.00						500,000.00	
J E I P (L P) E H C ., L .	19,000,000.00						19,000,000.00	
C ., L .	330,693,532.30		481,425.39				331,174,957.69	
Q K P M C ., L .	27,640,000.00						27,640,000.00	
	793,352,571.90		684,242.79	255,000.00			793,781,814.69	

Notes to the Financial Statements

F M E 30 J 2026
(A MB)

16 N (C)

16.3 Long-term equity investments *(Continued)*

16.3.2 I

Investee	B ( )	B	Increase/decrease in current period: Additional investment	Reduced investment	Profit or loss on investments recognised under the equity method	Adjustment to other comprehensive income	Changes in other equity	Cash dividends or profits declared to be distributed	Provision for impairment	Others	Balance (book value) as at the end of the period	Balance of provision for impairment as at the end of the period
H A M C L	9,316,664.65				831,424.73						10,148,089.38	
H L C L	56,002,864.79				-310,665.51						55,692,199.28	
	65,319,529.44				520,759.22						65,840,288.66	

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

16 N

(C)

16.4 Operating revenue and cost of sales

16.4.1 O

Item	Amount for the current period		A	
	Revenue	Cost		C
M	177,497,043.53	126,131,926.45	180,177,905.15	128,368,724.76
O	11,242,167.97	746,140.94	11,453,540.65	1,950.00
	188,739,211.50	126,878,067.39	191,631,445.80	128,370,674.76

B :

Item	Amount for the current period	A
	177,497,043.53	180,177,905.15
D	177,497,043.53	180,177,905.15
	11,242,167.97	11,453,540.65
M	8,212,124.44	8,183,172.17
	200,096.18	731,085.71
O	2,829,947.35	2,539,282.77
	188,739,211.50	191,631,445.80

Notes to the Financial Statements

F M E 30 J 2026

(A MB)

16 N *(C)*

16.4 Operating revenue and cost of sales *(Continued)*

16.4.2 D

Item	Time for fulfillment of performance obligations	Significant payment terms	Nature of goods promised to be transferred by the Company	Whether to be the principal responsible person	Amounts expected to be returned to customers that the Company has assumed	Types of quality assurance provided by the Company and related obligations
D		B	D		N	N

16.5 Investment income

Item	Amount for the current period	A
L -	5,000,000.00	
L -	520,759.22	1,526,125.08
	5,520,759.22	1,526,125.08

Definitions

A t、 C t、 B 、

B H B H C ., L、. (北京怡寧醫院有限公司), 、
P C 、 A t t 17, 2015, C ' 、 -
、 t 、

B 、 D B 、 、 、 C

C L C L P ' t C

C t K H C ., L、., 、
K H 、 t 、 P C, H M
B 、 H K E (C 、 : 2120)

CG C 、 C G C 、 、 A 、 C1 H K L
t

D ( ) 、 ( ) C

D ( ) 、 ( ) C , t
MB1.00 , t 、 、 、 t MB 、 t 、
t t 、 、 、

EGM C 、 、 、 、 t

G H t G H C ., L、. (溫州怡寧老年醫院有限公司),
、 P C 、 N 2, 2015,
C ' 、 - 、 t 、 , 、 、
、 , t、 、
、

G t t C 、 t 、

H ( ) 、 、 、 ( ) 、 、
C , t MB1.00 , 、 M B 、
H K E

HKD t t H K

Definitions

H K	H K A P C
H K L	G L E H K L ., ., .,
H K E	E H K L
H K H	H K H C ., L . (淮南康寧醫院有限公司), P C 22, 2017, C ' -
I ( )	N - . - . D E I P ' . A E I I P ' I C I
J H	J H C ., L . (縉雲舒寧醫院有限公司), P C F 15, 2019, C ' -
L K H	L K H C ., L . (龍泉康寧醫院有限公司), P C F 6, 2023, C '
L H	L H C ., L . (溫州鹿城怡寧醫院有限公司), P C A 2, 2020, C ' -
L C H	L C H C ., L . (台州市路橋慈寧醫院有限公司, L H C ., L .(台州市路橋怡寧醫院有限公司)), P C D 12, 2016, C ' -
M	M A P C

Definitions

M 、 C 、 M 、 C 、 D L 、 I A 、 C3 H K L

N C B

P ( ) D G (( ), ( ) , B E I I

P C P C H C ., L . (平陽長庚怡寧醫院有限公司), H P C J 14, 2021, C ,

P C C P ' C , H K , M

P 、 I D 、 MB1.80 (-) 10 30, 2026 IN E IM DI IDEND

Q H Q H C ., L . (衢州怡寧醫院有限公司), P C N 20, 2015, C , -

P 30, 2026

C B

MB P C

FO F O (C 571 L H K),

( ) ( ) C , MB1.00 , D ( ) H ( )

( ) ( ) ( )

Definitions

H H (深圳怡寧醫院, H C ., L . (深圳市怡寧醫院有限公司)), P C 22, 2014, C -

B M C

C O (C 622 L H K)

( ) H K L

( ) C

C C P C C L

N H N P H C ., L . (溫嶺南方精神疾病專科醫院有限公司), P C 20, 2018, C -

P I P I H ( ) C ., L . (怡寧心理互聯網醫院(溫州)有限公司), P C M 10, 2020, C

K H K H C ., L . (永嘉康寧醫院有限公司), P C D 12, 2012, C

K H K H C ., L . (樂清康寧醫院有限公司), P C 3, 2013, C

%

溫州康寧醫院股份有限公司
Wenzhou Kangning Hospital Co., Ltd.